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Human cardiac regeneration is limited by low cardiomyocyte replicative rates and progressive polyploidiza-
tion by unclearmechanisms. To study this process, we engineer a human cardiomyocytemodel to track repli-
cation and polyploidization using fluorescently tagged cyclin B1 and cardiac troponin T. Using time-lapse im-
aging, in vitro cardiomyocyte replication patterns recapitulate the progressive mononuclear polyploidization
and replicative arrest observed in vivo. Single-cell transcriptomics and chromatin state analyses reveal that
polyploidization is preceded by sarcomere assembly, enhanced oxidative metabolism, a DNA damage
response, and p53 activation. CRISPR knockout screening reveals p53 as a driver of cell-cycle arrest and pol-
yploidization. Inhibiting sarcomere function, or scavenging ROS, inhibits cell-cycle arrest and polyploidiza-
tion. Finally, we show that cardiomyocyte engraftment in infarcted rat hearts is enhanced 4-fold by the
increased proliferation of troponin-knockout cardiomyocytes. Thus, the sarcomere inhibits cell division
through a DNA damage response that can be targeted to improve cardiomyocyte replacement strategies.
INTRODUCTION
The adult human heart is characterized by insufficient regenera-
tive capacity that is related to low rates of existing cardiomyo-
cyte renewal (Bergmann et al., 2009) and lack of an appreciable
progenitor pool (van Berlo et al., 2014). By contrast, the capacity
for adult cardiac regeneration is well-established in other organ-
isms, such as salamander (Becker et al., 1974) and zebrafish
(Poss et al., 2002) and inversely correlates with cardiomyocyte
polyploidization rates (>2n; more than two sets of homologous
chromosomes). In zebrafish, it has been shown that regeneration
by cardiomyocytes that are >95%diploid (2n) can be completely
blocked by induction of polyploidization, supporting a causal link
(González-Rosa et al., 2018). Polyploidization has also been
demonstrated to regulate mammalian cardiac regeneration.
For example, in a panel of 120 genetically diverse mouse strains,
cardiomyocyte polyploidy rates were highly variable, genetically
determined, and inversely related to cardiomyocyte proliferative
responses induced by coronary artery ligation (Patterson et al.,
2017). How mammalian cardiomyocyte polyploidization is regu-
lated remains incompletely understood.
In humans, the majority of cardiomyocytes become mono-
nuclear polyploid before the second decade of life. While
both the total number of cardiomyocytes and nuclei per cardi-
omyocyte do not appreciably change, the average DNA con-
tent per cardiomyocyte increases 1.7-fold (Bergmann et al.,
2015). This pattern of mononuclear polyploidy suggests that
the human cardiomyocyte lacks the capacity to complete
mitosis. If cardiomyocytes could be coaxed to complete
mitosis, cardiomyocyte renewal could be enhanced to provide
new treatment options for individuals who suffer from heart
failure due to insufficient cardiomyocyte numbers, such as
that caused by myocardial infarction (MI) or congenital heart
disease. Patterns and mechanisms of human cardiomyocyte
polyploidization appear to be distinct from other mammalian
models such as the mouse, in which >90% of cardiomyocytes
are multinuclear, likely through a block in cytokinesis (Patter-
son et al., 2017). Due to the lack of a model for human
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cardiomyocyte polyploidization and limitations in obtaining
human heart samples, there is a large gap in our knowledge
regarding the molecular mechanisms underlying human cardi-
omyocyte polyploidization (Figure 1A).
To address this deficit, we engineered a cellular model to
study human cardiomyocyte replication and polyploidization
using induced pluripotent stem cell (iPSC) technology and cy-
clin B1 (CCNB1) as a reporter of replicative status. We em-
ployed live-cell imaging, single-cell RNA sequencing (scRNA-
seq), and chromatin-state analysis to comprehensively charac-
terize molecular determinants of polyploidization including
transcriptional signatures, signaling pathways, and gene regu-
latory motifs. Using a CRISPR screen adapted to study human
cardiomyocytes, we identified the tumor suppressor p53 as an
enhancer of cardiomyocyte polyploidization through CCNB1
inhibition. Our study implicates sarcomere assembly and func-
tion as an activator of p53 signaling through a DNA damage
response secondary to oxidative stress related to metabolic re-
programming. As proof of concept, we exploited these findings
to enhance human cardiomyocyte replication and promote re-







Figure 1. Engineering a human cardiomyocyte model to study polyploidization
(A) In vivo RNA-seq analysis of adult cardiomyocyte nuclei relative to fetal (Gilsbach et al., 2018) demonstrates downregulation of G2/M cyclins CCNB1 and
CCNB2 with persistence of G1/S cyclins CCND1 and CCND2.
(B) Overview of CRISPR methods to generate CCNB1-eGFP, TNNT2-T2A-NeoR, and TNNT2-mCherry iPSC lines to study polyploidization in differentiated
cardiomyocytes (CMs).
(C) Representative flow cytometry plots demonstrating that iPSCs relative to CMs expressmore uniformCCNB1 levels that progressively increase in S-phase and
peak in G2/M.
(D) Flow cytometry quantification of CCNB1-eGFP levels and Hoechst stain in CMs at differentiation day 20 to 40 shows progressive increase in DNA content
paralleling inhibition of CCNB1.
(E) Representative time-lapse confocal images of live CCNB1-eGFP and cTnT-mCherry CM cell-cycle progression and cytokinesis. White arrow denotes a CM
that undergoes cytokinesis into two daughter CMs. Scale bar, 10 mm.
(F) Replicative outcomes of 83 CCNB1+ CMs from time-lapse confocal imaging (green denotes CCNB1-eGFP expression and localization).
(G) CM mitosis relates to peak CCNB1-eGFP levels from time-lapse confocal imaging (n = 27 CCNB1+ CMs).
Data are nR 3 andmean ± SEM; significance assessed by ANOVAwith Holm-Sidak correction (D and G) and defined by *p% 0.05, **p% 0.01, and ***p% 0.001.
See also Figure S1 and Video S1.





Characterizing human cardiomyocyte replication and
polyploidization in vitro
To develop a model to study human cardiomyocyte replication
and polyploidization, we first analyzed RNA-seq data from hu-
man cardiomyocyte nuclei isolated from fetal and adult hearts,
including samples from heart failure patients (Gilsbach et al.,
2018). We observed that adult cardiomyocytes maintain
expression of G1/S cyclins CCND1 and CCND2 but not G2/M
cyclins CCNB1 and CCNB2, which diminish with age and do
not increase with stress such as heart failure (Figure 1A). While
the cell cycle is regulated at complex transcriptional and post-
transcriptional levels (Jensen et al., 2006), this pattern is
consistent with the observation that adult human cardiomyo-
cytes may retain some capacity for DNA synthesis but not
mitosis (Bergmann et al., 2009). As GFP fused to the C termi-
nus of CCNB1 can be exploited to track live replicating cells
in vitro (Hagting et al., 1998) and in vivo (Klochendler et al.,
2012) and could provide a tool to understand CCNB1 regula-
tion, we used CRISPR-Cas9 to fuse enhanced GFP (eGFP) to
endogenous CCNB1 in a human iPSC line (Figure 1B). Into
this CCNB1-eGFP iPSC line, we also fused either self-cleaving
T2A-NeoR or mCherry to cardiac troponin T (cTnT; encoded by
TNNT2) to allow iPSC-derived cardiomyocyte (CM) purification
and live-CM imaging, respectively (Figures 1B and S1A). We
confirmed that selection of TNNT2-T2A-NeoR CMs with G418
resulted in improved purity (Figures S1B and S1C) compared
to a well-established metabolic selection method (Tohyama
et al., 2013).
After confirming that GFP fused to CCNB1 did not alter iPSC
replication rates and cell-cycle status (Figures S1F–S1H), we
studied CCNB1-eGFP expression in both iPSCs and CMs co-
stained with Hoechst to analyze ploidy. We could distinguish
4n cells that are in G2/M using CCNB1-eGFP expression status
(denoted as CCNB1+). iPSCs expressed uniform levels of
CCNB1 in early S phase that peaked in G2/M (Figures S1D
and S1E), in accord with previous studies (Clute and Pines,
1999; Klochendler et al., 2012). Relative to iPSCs, CMs ex-
pressed distinctly different CCNB1 levels. CMs expressed lower
CCNB1 levels in S phase and with greater heterogeneity in G2/M
(Figure S1E). We also observed 4n+ (>4n) CCNB1+ CMs, sug-
gesting progressive polyploidization. CMs, but not iPSCs, also
contained 4n and 4n+ cells that were CCNB1–, which was not
due to a transient cell-cycle arrest or CM doublets, as persis-
tence of polyploidy was documented in CMs cultured for 48 h af-
ter fluorescence-activated cell sorting (FACS) (Figure S1I). To
determine how CCNB1-eGFP expression related to other cell-
cycle-regulated factors, we utilized flow cytometry to analyze
CMs immunostained for cell-cycle markers and anti-GFP co-
stain (Figures S1J and S1K). 45% of CCNB1+ CMs were in S-
phase as determined using a 30-min pulse with 5-ethynyl-20-de-
oxyuridine (EdU). 68% and 62% of CCNB1+ CMs expressed
replication markers Ki67 and Aurora, respectively. Finally,
1.7% of CCNB1+ CMs were in M-phase as determined by phos-
pho-Histone H3 (p-H3) expression (Preuss et al., 2003). Because
CCNB1– CMs did not express these makers, we conclude that
CCNB1-eGFP is a marker of S and G2/M phases as observed
in other cell types (Zielke et al., 2014). We also segmented
CCNB1+ CMs into CCNB1+high and CCNB1+low, which demon-
strated that CCNB1+low CMs were enriched in S-phase, while
CCNB1+high CMs were in enriched in G2/M-phase (Figures S1L
and S1M), which has also been observed in other cell types (In-
nocente et al., 1999; Strauss et al., 2018).
To test known effectors of cardiomyocyte replication, we var-
ied differentiation time (Figures 1C and 1D), ambient oxygen (Fig-
ure S1N), and insulin (Figure S1O) and performed knockdown of
MEIS1 (Figure S1P), a repressor of in vivomouse cardiomyocyte
replication (Mahmoud et al., 2013). From differentiation day 20 to
40, the proportion of 4n CCNB1+ CMs progressively decreased,
while 4n CCNB1– CMs increased. Hypoxia (2.5% O2), insulin,
and MEIS1 knockdown all increased the relative proportion of
4n CCNB1+ CMs, in accord with previous replication studies
(McDevitt et al., 2005; Nakada et al., 2017). These results
demonstrate that CMs recapitulate age-dependent progressive
CCNB1 inhibition and polyploidization and respond similarly to
previously established regulators of in vivo cardiomyocyte
replication.
To understand CM replicative outcomes and potential rela-
tionships with CCNB1 expression, we performed time-lapse
confocal imaging studies of CCNB1-eGFP cTnT-mCherry
iPSCs and CMs (Figure 1E; Video S1). We first observed
that all iPSCs expressed CCNB1 in the uniform and oscilla-
tory pattern observed in other cell types (Clute and Pines,
1999; McDevitt et al., 2005), starting in the cytoplasm fol-
lowed by nuclear entry and degradation preceding cytoki-
nesis. Among 83 CCNB1+ CMs analyzed, 75% lost CCNB1
expression prior to completing mitosis, either in the cyto-
plasm or immediately after nuclear entry, which is consistent
with the greater CCNB1 expression heterogeneity observed
in CMs by flow cytometry. Among the 21 CMs observed to
undergo nuclear entry of CCNB1 followed by mitosis, nine
completed cytokinesis, five became multinuclear, and seven
were inconclusive within 24 h of observation (Figure 1F). As
we observed high CCNB1 heterogeneity in 4n CCNB1+
CMs relative to iPSCs, we considered whether CCNB1
expression levels and localization may relate to CM replica-
tive outcomes. In CMs that completed mitosis, we observed
the highest CCNB1 levels that were associated with CCNB1
nuclear entry (Figure 1G), with CCNB1 levels being the lowest
in CMs that degraded CCNB1 prior to nuclear entry and in-
termediate in CMs with nuclear CCNB1 entry without mitosis,
in accord with CM immunostaining results (Figure S1M).
Taken together, we quantified replicative outcomes of
CCNB1+ CMs and demonstrated that 75% do not complete
mitosis in association with low CCNB1 levels that results in
mononuclear polyploidy. Another 11% of the CCNB1+ CMs
complete cytokinesis to generate two daughter CMs, while
6% result in a multinuclear polyploid CM, which did not relate
to CCNB1 levels (Figure S1Q). The high occurrence of mono-
nuclear polyploidy that we observed in CCNB1+ CMs is
consistent with studies from in vivo human cardiomyocytes
(Mollova et al., 2013) and illuminates a previously unde-
scribed mitotic checkpoint related to CM-specific CCNB1
expression heterogeneity that could potentially be targeted
to enhance CM replication and reduce polyploidization.




CRISPR genetic screen identifies TP53 as a regulator of
CM polyploidization and CCNB1
We next sought to identify genetic regulators of CM replication
and polyploidization by implementing a CRISPR knockout
screen. Because pooled genetic screens to study replication
have commonly utilized cell lines with high replicative rates
(Hart et al., 2015; Marcotte et al., 2012), we had to adapt our
strategy to account for low replication and high polyploidization
in CMs. Our approach to address these inherent limitations was
to utilize the CCNB1-eGFP CM model to provide a method to
distinguish 4n CCNB1+ CMs from 4n CCNB1– (cell cycle ar-
rested) and 2n (Figure 2A). Using FACS, we could collect these
three populations and identify genetic modifiers of polyploidiza-
tion and CCNB1 expression by tracking population-dependent
sgRNA enrichment or depletion (Figure 2B).
To perform the screen, we transduced lentiviral SpCas9 into
CCNB1-eGFP TNNT2-T2A-NeoR iPSCs. The genome-wide Bru-
nello sgRNA library (Doench et al., 2016) was then transduced at
a lowmultiplicity of infection to optimize for one sgRNAper iPSC,
followed by selection and expansion over two passages to mini-
mize sgRNA drift. We then differentiated iPSCs to CMs, purified
by G418 selection, and sorted live, Hoechst-stained CMs by
FACS to collect the three desired populations (Figure 2A). We
sequenced sgRNA recognition sites and performed Model-
based Analysis of Genome-wide CRISPR-Cas9 Knockout (MA-
GeCK) (Li et al., 2014) to identify gene-specific sgRNAs enriched
in 4nCCNB1+ and depleted in 4nCCNB1– relative to 2nCMs.We
used this genome-wide screen to identify candidate genes that
satisfied moderate stringency cutoffs (false discovery rate
[FDR] <0.25; Table S2) and designed an sgRNA sub-library for in-
dependent replication with higher stringency (FDR <0.005; Table
S2). Using this strategy, we identified the tumor suppressor p53
as both a promoter of CM polyploidy and repressor of the pro-
portion of CMs that express CCNB1, as all four sgRNAs targeting
TP53 were consistently enriched in 4n CCNB1+ and depleted in
4n CCNB1– relative to 2n CMs (Figure 2C).
We next tested how p53 regulates the CM cell cycle. We
started by quantifying protein levels of p53 and p21, a direct
p53 transcriptional target (el-Deiry et al., 1993), in lysates ob-
tained from 4n and 2n CCNB1– CMs. 4n relative to 2n CMs ex-
hibited increased p53 and p21 levels (Figures 2D and 2E). We
then studied a p53 knockdown (KD) model by transducing
CMs with lentiviral SpCas9 and an sgRNA targeting TP53, which
decreased p53 and p21 levels and increased levels of active,
phosphorylated CCNB1 relative to treatment with a non-target-
ing (NT) control sgRNA (Figures 2F and 2G; Toyoshima-Mori-
moto et al., 2001). In accord with our CRISPR knockout screens,
p53 KD increased the proportion of CCNB1+ CMs and reduced
polyploidization (Figure 2H). Additionally, immunostaining for
cell-cycle markers following p53 KD revealed increased positiv-
ity for Ki67, Aurora, and p-H3 (Figure 2I), as well as enhanced
EdU incorporation. This result in CMs is consistent with studies
in other cell types implicating p53 as an inhibitor of G1/S and
G2/M checkpoints (Agarwal et al., 1995; Bunz et al., 1998; Inno-
cente et al., 1999). To specifically address the role of p53 inG2/M
checkpoint regulation, we FACS-enriched p53 KD and NT con-
trol CMs post-G1/S checkpoints by collecting CCNB1+ CMs.
We then quantified CCNB1+ CM replicative outcomes using
live-cell imaging as done previously (Figure 1F). We observed
that p53 KD increased the proportion of mitotic CMs (Figure 2J)
and the ratio of 2n relative to 4n CMs (Figure 2K).
To assesswhether p53 activation could regulate CMcell-cycle
checkpoints, we treated CMs with the p53 activator Nutlin-3
versus DMSO control (Figures S2A and S2B; Vassilev et al.,
2004). Nutlin-3 treatment reduced the proportion of CCNB1+
CMs and increased polyploidization (Figure 2L). Nutlin-3 treat-
ment also reduced Ki67, Aurora, and p-H3 expression, as well
as EdU incorporation (Figure 2M), which confirmed that p53 ac-
tivates G1/S andG2/M checkpoints in CMs. To specifically study
the G2/M checkpoint, we again FACS-collected CCNB1+ CMs
and immediately treated with Nutlin-3 or DMSO. We then per-
formed time-lapse imaging to quantify replicative outcomes,
which demonstrated a decrease in the proportion of mitotic
CMs (Figure 2N) and the ratio of 2n relative to 4nCMs (Figure 2O).
Taken together, these results demonstrate that p53 promotes
CM polyploidization through G2/M checkpoint activation and
CCNB1 repression.
Chromatin-state segmentation reveals enhancers
associated with polyploidy
Gene regulatory sequences and changes in chromatin state are
known to be important for cardiac development and disease
(Gilsbach et al., 2018). To determine epigenetic changes associ-
ated with CM polyploidization, we analyzed FACS-collected 2n
and 4n CCNB1– CMs by chromatin immunoprecipitation with
DNA sequencing (ChIP-seq) to assess histone modifications.
Each ploidy state was imputed in conjunction with Roadmap Ep-
igenome data and segmented using a 25-state model, as we
have previously employed (VanOudenhove et al., 2020; Wilder-
man et al., 2018).We generated expected numbers of each chro-
matin state (Figures S3A and S3B) and identified activation of
early heart specification genes, such as NKX2-5 (Figure S3C).
To assess how our CMs compared to primary human heart sam-
ples, we performed t-Distributed Stochastic Neighbor Embed-
ding (tSNE) analysis of H3K27ac levels, typically associated
with tissue-specific enhancer activation, at segments identified
as enhancer states in CMs and Roadmap segmentations (Fig-
ure 3A). Globally, 2n and 4n CCNB1– CMs were similar, as their
tSNE positions were inseparable. In addition, global CM
enhancer activation clustered between in vivo adult heart (HRT)
and fetal heart samples but were distinct from stem cells
(ESCs) and non-CM ESC derivatives.
We next sought to determine whether regulatory elements
were differentially activated between 2n and 4n CCNB1– CMs.
To do this, we compared H3K27ac, H3K4me2, and H3K4me3
signals at promoter and enhancer chromatin-state segmenta-
tions (Figure 3B). The majority (~96%) of regulatory sequences
had similar levels of activation in both ploidy states. Among
differentially activated enhancers (Table S3), we found that 2n-
biased enhancer segments were enriched in binding sites for
factors regulating stem cell maintenance and proliferation,
including SOX6 that has been shown to regulate cardiomyocyte
development in vivo (Hagiwara et al., 2000), brachyury that is
necessary for cardiogenic mesoderm differentiation (Herrmann
et al., 1990), and FOX family members that regulate cell prolifer-
ation andmitosis (Laoukili et al., 2005; Figure 3B). GeneOntology
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Figure 2. CRISPR screen identifies p53 as an activator of CM polyploidy and inhibitor of CCNB1
(A) Schematic used to conduct CRISPR screen in CMs differentiated from iPSCs transduced with SpCas9 and sgRNA library, as well as CM collection strategy by
FACS.
(B) Simplified distribution of three theoretical sgRNAs, showing sgRNAB (red) enriched in 4n CCNB1+ CMs and depleted in 4n CCNB1– relative to 2n, as it targets
a putative activator of polyploidization and inhibitor of CCNB1 expression.
(C) All four sgRNAs targeting TP53 are enriched in 4n CCNB1+ CMs and depleted in 4n CCNB1– relative to 2n across three biological CRISPR sub-screen
replicates.
(D) Representative immunoblots and (E) quantification demonstrate increased p53 and p21 levels in FACS-collected 4n CCNB1– CM protein lysates compared to
2n.
(F) Representative immunoblots and (G) quantification of p53, p21, phospho-CCNB1, and GAPDH protein levels illustrate that p53 knockdown (KD) by TP53
sgRNA compared to non-targeting (NT) control results in p21 reduction and CCNB1 induction.
(H) p53 KD increases the proportion of CCNB1+ CMs while decreasing the proportion of CCNB1– 4n CMs, as quantified by flow cytometry.
(I) Flow cytometry analysis of immunostained p53 KD CMs demonstrates increased positivity for EdU, Ki67, Aurora A, and p-H3.
(J) Time-lapse imaging outcomes of p53 KD CCNB1+ CMs that were treated with Cas9 + NT or TP53 sgRNA 5–7 days prior to FACS collection and imaging (n =
488 CMs from 3 experiments).
(K) Ratio of diploid:polyploid outcomes from time-lapse imaging of p53 KD CCNB1+ CMs in (J).
(L) Nutlin-3 decreases the proportion of CCNB1+ CMs while increasing the proportion of CCNB1– 4n CMs, as quantified by flow cytometry.
(M) Nutlin-3 decreases the proportion of EdU+, Ki67+, Aurora A+, and p-H3+ CMs.
(N) Time-lapse imaging outcomes of FACS-collected CCNB1+ CMs (post-G1/S) treated with either DMSO or Nutlin-3 prior to imaging (n = 416 CMs from 3
experiments).
(O) Ratio of diploid:polyploid outcomes from time-lapse imaging of Nutlin-treated CCNB1+ CMs in (N).
Data are nR 3 and mean ± SEM; significance assessed by FDR-adjusted p (C) or t test (D–O) and defined by *p% 0.05, **p% 0.01, and ***p% 0.001. See also
Figure S2 and Table S2.




(GO) analysis of genes predicted to be regulated by these 2n-
biased enhancers showed enrichment of genes related to stem
cell differentiation and division (Figure 3C). In contrast, 4n-biased
enhancer state segments were enriched for motifs including
MEF2 (Myocyte Enhancer Factor 2) family members such as
MEF2A, which activates muscle-specific genes required for
normal heart function (Naya et al., 2002), as well as MEIS1, a
known repressor of in vivo cardiomyocyte replication (Mahmoud
et al., 2013). GO analysis supported these results, as putative 4n-
biased enhancer target genes were enriched in functions related
to cardiac chamber development and myofibril assembly (Fig-
ure 3C). 4n-biased enhancers were also enriched in binding sites
for p53 and the antioxidant NRF2. For example, CDKN1A en-
codes for p21, a potent cyclin-dependent kinase inhibitor, which
contains multiple 4n-biased enhancers overlapping previously
validated p53 binding sites (Figure 3D; el-Deiry et al., 1993;
Nguyen et al., 2018). In summary, CM polyploidization is associ-
atedwith distinct chromatin regulatory element usage character-
ized, in part, by loss of stemness and gain of myofibril assembly,
oxidative stress, and p53 signaling activation.
Single-cell transcriptomics to predict determinants of
CM replication and polyploidization
To determine and exploit CM heterogeneity underlying poly-
ploidization and replication, we studied the CCNB1-eGFP CM
model using scRNA-seq. We FACS-collected 2n, 4n CCNB1+,
and 4n CCNB1– CMs in 384-well plates (Figure 4A) and then
generated single-cell transcriptomics data using a plate-based
30 end counting method (Table S4). Using Seurat (Butler et al.,
2018), we visualized cell clusters using Uniform Manifold
Approximation and Projection (UMAP) (Figure 4B). We next
segregated the seven clusters by CCNB1 and ploidy status (Fig-
ure 4C) and observed that CMs clustered byCCNB1 expression,
as clusters 4 and 6 were non-contiguous with the other clusters
and uniformly expressed CCNB1 (Figure 4D) and other G2/M




Figure 3. Polyploidy is associated with distinct enhancer activation states
(A) tSNE created using H3K27ac signal at enhancers called by ChromHMM segmentation across 127 tissues including 2n and 4n CCNB1– CMs, Roadmap
Epigenome, and cardiomyocyte nuclei isolated from human hearts (Gilsbach et al., 2018). Samples are color coded by tissue group.
(B) Plot of differential enhancer motif enrichment. Dot size reflects the percentage of enhancers containing the given motif and color represents the directionality
andmagnitude of the log p value difference between 2n and 4n enhancer enrichment. Indicatedmotifs are significantly enriched in at least one sample and have a
differential R2 on log scale.
(C) GO term analysis of genes predicted to be regulated by enhancers increased in 2n and 4n CMs, as determined by GREAT.
(D) UCSC Genome Browser snapshot of the locus containing CDKN1A, a cyclin-dependent kinase inhibitor with regulatory elements overlapping p53 binding
sites that are more activated in 4n compared to 2n CMs. At the top are p53 binding sites, chromatin-state segmentations for 2n and 4n CMs, followed by imputed
signals for five histone marks, and a track indicating vertebrate conservation. ChIP-qPCR primer locations are denoted that relate to Figure 5K.
See also Figure S3 and Table S3.




lower CCNB1 transcript levels were distributed across the other
clusters. 4n CCNB1– CMs were abundant in clusters 0 and 1
(containing ~66% of polyploid CMs), and 2n CMs were more
abundant in clusters 2, 3, and 5 (containing ~60% of diploid
CMs) (Figure 4E). Additionally, we confirmed that single-cell
expression heterogeneity was not related to changes in CM dif-
ferentiation subtypes such as determined by cardiac chamber-
specific marker expression across clusters (Figure S4B). Tran-
script and protein expression data also reflected the fetal-like
differentiation state of CMs based on the predominance of skel-
etal (TNNI1; encodes ssTnI) relative to cardiac (TNNI3; encodes
cTnI) troponin I isoforms (Figures S4B and S4C; Bedada et al.,
2014).
To identify transcriptional networks related to polyploidiza-
tion, we next performed gene set enrichment analysis (GSEA)
using the top 100 significantly upregulated genes (adjusted p
% 0.05) in the CCNB1-abundant and polyploid-abundant clus-
ters (Table S4). The CCNB1-abundant clusters exhibited high
levels of genes involved in mitosis, cell-cycle regulation, and
cell division (Figure 4F). In contrast, polyploid-abundant clus-
ters exhibited higher levels of genes related to p53 signaling
and myofibril assembly (Figure 4G), in accord with our chro-
matin segmentation analysis, as well as mitochondrial function
and oxidative metabolism, which have been shown to asso-
ciate with murine polyploidization in vivo (Jiang et al., 2020;
Puente et al., 2014), suggesting that these processes may
also promote human CM polyploidization. In summary, we ex-
ploited expression heterogeneity to identify molecular signa-
tures of CM polyploidization and CCNB1 regulation including
oxidative stress, myofibril assembly, and p53 signaling
activation.
We next exploited single-cell expression heterogeneity using
Slingshot pseudotime analysis (Street et al., 2018) to generate
cell trajectories to computationally predict molecular determi-
nants of CM replication and polyploidization decisions. This
analysis identified two independent trajectories: trajectory 1,
which starts in diploid-abundant clusters and ends in
CCNB1-abundant clusters (Figure 4H) and trajectory 2, starting
in diploid-abundant clusters and ending in polyploid-abundant
clusters (Figure 4K). Given that trajectories resembled poly-
ploidization decisions, we used Slingshot to study the top
100 genes whose expression related to the two trajectories.
GSEA of the genes defining the G2/M-abundant trajectory 1
identified mitosis, cell-cycle checkpoint, and proliferation
markers (Figure 4I), such as CDK1, MKI67, and UBE2C (Fig-
ure 4J), which are highly expressed in the late pseudotime
CMs of trajectory 1. We then performed this analysis on trajec-
tory 2 to identify genes predicted to regulate polyploidization,
which included muscle contraction and sarcomere genes (Fig-
ure 4L), such as MYH6 and TPM1 (Figure 4M), which increased
with pseudotime in the polyploid-abundant clusters. Moreover,
GSEA also identified genes upregulated by reactive oxygen
species, p53 pathway activation such as GADD45B and
CDKN1A (Figure 4M), and genes related to DNA damage-
induced regulation of p53 (Childs et al., 2018; Monte et al.,
2003). These results additionally implicate sarcomere function,
DNA damage, and p53 pathway activation in the genesis of CM
polyploidy.
Sarcomere function inhibits CCNB1 through p53
activation
To study the role of sarcomere function in CM replication and
polyploidization, we engineered sarcomere assembly deficient
CM models based on knowledge that the troponin (Tn) complex
is necessary for sarcomere assembly and contractile function
(Huang et al., 1999; Nishii et al., 2008). We used CRISPR-Cas9
to generate iPSC lines containing either a homozygous frame-
shift in TNNT2 (denoted cTnT-KO), as we have previously em-
ployed (Pettinato et al., 2020), or frameshifts in both TNNI1 and
TNNI3 (denoted TnI-DKO). The engineered CMs showed the ex-
pected absence of their respective troponin isoforms (Figures 5E
and 5G), and neither KO line visibly contracted, in contrast to
wild-type (WT) CMs that spontaneously contract. Correspond-
ingly, a-actinin immunofluorescence revealed that both KO lines
had impaired sarcomere formation, lacking the well-formed Z-
disks that result from myofibril bundling (Figure 5A). In support
of our hypothesis, we observed decreased polyploidization in
sarcomere-deficient CMs compared to controls (Figures 5B
and 5C), increased CCNB1+ CMs (Figure 5D), and increased
positivity of EdU, Ki67, Aurora, and p-H3 (Figure S5A). We next
tested whether CCNB1 overexpression could prevent the high
polyploidization and low CCNB1 observed in sarcomere-con-
taining CMs. We transduced lentivirus encoding CCNB1 fused
to a nuclear localization signal (NLS-CCNB1), as we found that
nuclear CCNB1 promotedmitosis (Figure 1G), to provide overex-
pression co-incident with sarcomere assembly in WT CMs,
which reduced CM polyploidization and increased the propor-
tion of CCNB1+CMs (Figures S5B). Taken together, these results
demonstrate that myofibrils promote polyploidization, and this
can be antagonized by enhancing CCNB1 levels.
With multiple datasets implicating a link between the sarco-
mere and p53 activation in promoting polyploidization and
CCNB1 inhibition, we analyzed WT, cTnT-KO, and TnI-DKO ly-
sates for relevant protein marks. We confirmed increased p-
CCNB1 and decreased p21 in both Tn-KO models (Figures
5E–5H), similar to our p53 KD studies. Unlike p53 KD, however,
total p53 levels were not consistently different in Tn-KO CMs
relative to WT. Additionally, treatment with verapamil, an L-
type calcium channel blocker that inhibits sarcomere function
(De Deyne, 2000; Lam et al., 2019), also demonstrated a similar
molecular phenotype including increased p-CCNB1, decreased
p21, and no change in total p53 protein levels (Figures 5I and 5J).
As total p53 levels may not reflect p53 activity (Bode and Dong,
2004) and p21 can be activated by other factors (Jung et al.,
2010), we additionally studied WT and cTnT-KO CMs by p53
ChIP-qPCR targeting known p53-enriched response elements
on CDKN1A (Nguyen et al., 2018). Relative to WT, we found
decreased enrichment of p53 at polyploidy-associatedCDKN1A
response elements in cTnT-KO CMs (Figure 5K), suggesting that
inhibiting sarcomere assembly decreases p53 activity through a
post-translational mechanism.
Direct molecular connections between sarcomere function
and p53 activation have not been well established in human car-
diomyocytes. We hypothesized that sarcomere function could
regulate p53 through a DNA damage response, as sarcomere
gene expression was related to activation of oxidative stress
pathways by pseudotime (Figure 4L), and polyploid CMs
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Figure 4. scRNA-seq analyses predict mechanisms of polyploidization
(A) Representative FACS plot of CCNB1-eGFP CMs stained with Hoechst to collect 2n, 4n CCNB1+, and 4n CCNB1– single-CMs in wells of 384-well plates.
(B) UMAP clustering analysis by Seurat uncovers seven CM clusters.
(C–E) Segregation of Seurat clusters by (C) CCNB1 and ploidy status identifies clusters abundant for 4n CCNB1– (0 and 1), 2n (3 and 5), and 4n CCNB1+ CMs (4
and 6), in accord with (D) CCNB1 transcript levels and (E) proportional breakdown of Seurat clusters by sorted cell type.
(F) Gene set enrichment analysis (GSEA) using the top 100 significantly upregulated genes (adjusted p% 0.05) from clusters 4 and 6 (containing ~94% CCNB1+
CMs) identified transcripts related to the cell cycle, mitosis, and cell division.
(G) GSEA using the top 100 significantly upregulated genes from clusters 0 and 1 (containing ~66% of polyploid CMs) identified transcripts related to sarcomere
function and structure, oxidative metabolism, and p53 signaling.
(H) Single CMs are displayed using UMAP overlapped with Slingshot pseudotime trajectories. Trajectory 1 begins in the diploid-abundant cluster 5 and ends in
the CCNB1-abundant cluster 4.
(I and J) The top 100 genes defining trajectory 1 have (I) functions related to mitosis and the cell cycle, such as (J) G2/M checkpoint (CDK1 and UBE2C) and
proliferation markers (MKI67).
(K–M) Trajectory 2 (K) begins in the diploid-abundant cluster 5 and ends in the polyploid-abundant cluster 0 and is (L) defined by genes related to sarcomere
function and structure, oxidation, and p53 activity, such as (M) MYH6, TPM1, and CDKN1A, suggesting a causal relationship with polyploidization.
See also Figure S4 and Table S4.
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Figure 5. Cellular and molecular consequences of sarcomere assembly
(A) Representative immunofluorescence images of wild-type (WT) control and cardiac troponin T knockout (cTnT-KO) CMs stained for a actinin (green; sarcomere
Z-disk) and DAPI (blue; nuclei). KO of troponin, either cTnT-KO or double KO of skeletal and cardiac troponin I (TnI-DKO), leads to lack of striated sarcomere Z-
disks. Scale bar, 10 mm.
(B and C) Flow cytometry of Hoechst-stained CMs demonstrates decreased polyploidy in (B) cTnT-KO and (C) TnI-DKO CMs relative to WT.
(D) Flow cytometry of CCNB1-stained WT and TnI-DKO CMs demonstrates increased proportion of CCNB1+ CMs with TnI-DKO, which reduces with age.
(E and F) Representative immunoblots (E) with (F) quantification of protein lysates fromWT and cTnT-KO CMs probed for cTnT, p53, p21, phospho-CCNB1, and
GAPDH.
(G and H) Representative immunoblots (G) with (H) quantification of protein lysates fromWT and TnI-DKO CMs probed for TnI (cardiac and skeletal), p53, p21, p-
CCNB1, and GAPDH.
(I and J) Representative immunoblots (I) with (J) quantification of protein lysates from day 20WT CMs treated with verapamil from day 9 and probed for p53, p21,
p-CCNB1, and GAPDH.
(K) Anti-p53 ChIP-qPCR of WT and cTnT-KO CMs targeting previously reported p53-bound ChIP-seq peaks directly upstream of CDKN1A (Nguyen et al., 2018),
which demonstrates decreased p53 binding of CDKN1A in cTnT-KO CMs at three separate genomic sites (see Figure 3D).
(legend continued on next page)




exhibited increased oxidative signaling pathway activation (Fig-
ure 4G). To test this, wemeasured levels of both phospho-H2AX,
an epigenetic marker of DNA damage (Ayoub et al., 2008), and 8-
oxo-20-deoxyguanosine (8-OHdG), a DNA-level marker highly
specific for oxidative damage (Du et al., 2016). Both markers ex-
hibited decreased levels in the absence of sarcomere assembly
(Figures 5L–5N). To assess potential sources of sarcomere-
dependent oxidative damage, we quantified mitochondrial
mass and superoxide production by flow cytometry analysis of
MitoTracker- and MitoSOX-stained CMs, respectively (Fig-
ure 5O). We observed reductions in both parameters in the
absence of sarcomere assembly, as well as reductions in oxygen
consumption rates (Figures 5P and 5Q). To test whether inhibi-
tion of oxidative stress could rescue the reduced proportion of
CCNB1+ CMs observed in sarcomere-containing CMs, we
treated WT CMs with the antioxidant N-acetylcysteine (NAC).
NAC increased the proportion of CCNB1+ CMs and reduced pol-
yploidization (Figure S5C).
To identify potential molecular linkages between sarcomere
function and oxidative metabolism, we hypothesized that sarco-
mere function-dependent changes in ATP hydrolysis could be
sensed by AMP-activated protein kinase (AMPK), which is an
activator of oxidative metabolism (Herzig and Shaw, 2018). To
test this, we measured the levels of AMPK phosphorylation (p-
AMPK) in cTnT-KO relative to WT CMs. We observed that
cTnT-KO CMs exhibited reduced p-AMPK levels (Figures 5R
and 5S), which was similarly observed after acute inhibition of
sarcomere function using verapamil in WT CMs (Figures 5T
and 5U). While AMPK can also be activated by calcium (Herzig
and Shaw, 2018), we found no differences in calcium transients
between cTnT-KO relative to WT CMs (Figure S5D), and verap-
amil treatment had no effect on p-AMPK levels in cTnT-KO
CMs despite inhibition of calcium transients (Figures S5D–
S5F). Taken together, these functional studies illuminate how
the sarcomere promotes polyploidization through metabolic re-
programming in association with AMPK activation, oxidative
stress, and, ultimately, p53 activation.
Inhibiting sarcomere function enhances CM
engraftment and proliferation in a MI model
As sarcomere function decreased CM replication and increased
polyploidization, we hypothesized that sarcomere inhibition
could improve CM engraftment in a myocardial infarction (MI)
rat model, since improving engraftment rates has been a long-
standing obstacle for cell-therapy strategies (Laflamme et al.,
2007; Zhu et al., 2018). To test this, rats underwent ischemia/re-
perfusion (I/R) surgery to induce MI, followed by injection of 1 3
107 human CMs (WT or TnI-DKO) 4 days later (Figure 6A), as we
have previously described (Fernandes et al., 2010; Weyers et al.,
2020). Bromodeoxyuridine (BrdU) was injected periodically to
measure DNA synthesis, and rats were sacrificed 3 months
post-transplantation for histological analysis. Sections of the
left ventricle (LV) were immunohistochemically stained for
b-myosin heavy chain (b-MHC), the predominant isoform ex-
pressed in human CMs, which was used to visualize the hu-
man-derived graft (Figure 6B). WT CMs produced a mean graft
size of 0.11% ± 0.05% of the LV, while TnI-DKO CMs produced
a size of 0.46% ± 0.10%, more than 4-fold larger (Figure 6C; p =
0.0041), demonstrating improved in vivo cardiac engraftment
when transplanting TnI-DKO CMs. Additionally, immunofluores-
cence was performed on LV sections to assess proliferation of
human CMs following in vivo engraftment using cumulative
BrdU incorporation and Ki67 expression as markers. Sections
were labeled for b-MHC (human CMs), Hoechst (nuclei), and
either BrdU (Figure 6D) or Ki67 (Figure 6F). BrdU staining demon-
strated that WT CMs were 0.40% ± 0.22% BrdU+, while TnI-
DKO CMs were 1.52% ± 0.30% BrdU+ (Figure 6E; p = 0.012),
and Ki67 staining demonstrated that WT CMs were 0.14% ±
0.08% Ki67+, whereas TnI-DKO CMs were 0.50% ± 0.10%
Ki67+ (Figure 6G; p = 0.021). To also assess the contribution of
cellular apoptosis to the engraftment phenotypes, we performed
terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) assays at 3 months post-engraftment, in which we
observed no difference in apoptosis between WT and TnI-DKO
CMs (Figure S6). We conclude that sarcomere function impairs
CM engraftment and remuscularization after cell therapy, in
part, through reduced replicative capacity.
DISCUSSION
The principal finding of this study is that human cardiomyocyte
polyploidy and cell-cycle arrest are driven by downregulation
of cyclin B1 by the tumor suppressor p53. We provide evidence
that p53 is activated through a DNA damage response that is
promoted by reactive oxygen species, which appear to result
from mitochondrial metabolism that is enhanced by sarcomere
contraction, the principal ATP-consuming process of the cardio-
myocyte. We show that this pathway can be exploited to
enhance cardiac remuscularization following cell transplantation
in a rat model of myocardial infarction.
MIs are common events secondary to acute coronary artery
blockages that result in large-scale cardiomyocyte death and
progressive heart failure due to inadequate mechanical function
(O’Gara et al., 2013). Low adult cardiomyocyte replication rates
(L and M) Representative immunoblots probed for phospho-H2AX and GAPDH (L) with (M) quantification demonstrates sarcomere assembly activates a DNA
damage response in WT CMs.
(N) Quantification of genomic DNA lysates from WT and cTnT-KO CMs probed via ELISA for 8-OHdG, a marker of oxidative DNA damage.
(O) Flow cytometry quantification of MitoTracker andMitoSOX dyes inWT and cTnT-KOCMs demonstrates reducedmitochondrial content and ROS in cTnT-KO
CMs.
(P and Q) Seahorse Mito Stress oxygen consumption rates (OCR) (P) with (Q) quantification shows a decrease in respiration across all parameters in cTnT-KO
CMs compared to WT, demonstrating that sarcomere assembly promotes oxidative metabolism.
(R and S) Representative immunoblots (R) with quantification (S) of protein lysates from WT and cTnT-KO CMs probed for p-AMPK, AMPK, and GAPDH.
(T and U) Representative immunoblots (T) with quantification (U) of protein lysates from WT CMs treated with verapamil for 1 h and probed for p-AMPK, AMPK,
and GAPDH.
Data are n R 3 and mean ± SEM; significance assessed by t test and defined by p > 0.05 (ns), *p % 0.05, **p % 0.01, and ***p % 0.001. See also Figure S5.




exacerbate this condition as yearly turnover rates have been
estimated to be <1% (Bergmann et al., 2015). Human cardio-
myocytes remain diploid during the first year of life, but age-
dependent polyploidization and replicative arrest occur over
the first 2 decades of life (Bergmann et al., 2015) by incompletely
understood mechanisms. New knowledge of how to control
endogenous human cardiomyocyte replication or to implant
exogenous human cardiomyocytes as cell therapy could be
transformative for these patients. To date, the majority of cardi-
omyocyte replication studies have focused on non-human
model systems but have revealed that low ambient oxygen,
low-pressure circulation, glycolytic metabolism, and absence
of polyploidy enhance cardiac regenerative capacity (Vivien
et al., 2016). The knowledge of the conservation of these replica-








Figure 6. Sarcomere-deficient CMs enhance
in vivo cardiac engraftment
(A) Overview of experimental workflow used to
study cardiac engraftment of human CMs in a rat
model of myocardial infarction (MI).
(B) Representative immunohistochemistry images
and (C) quantification of rat left ventricle (LV) sec-
tions stained for human b-myosin heavy chain
(b-MHC) to assess human CM graft size, which
was increased when using TnI-DKO CMs
compared to WT. Scale bar, 250 mm.
(D–G) Representative immunofluorescence im-
ages and quantification of rat LV sections probed
for b-MHC (green; human CMs), Hoechst (blue;
nuclei), and either (D and E) BrdU (magenta; cu-
mulative proliferation) or (F and G) Ki67 (magenta;
active proliferation), which show increased %
BrdU+ and %Ki67+ human CMs when using TnI-
DKO for engraftment, demonstrating enhanced
proliferative capacity compared to WT CMs. Scale
bars, 25 mm (D) or 50 mm (F).
Data are n R 3 and mean ± SEM; significance
assessed by t test and defined by *p % 0.05 and
**p % 0.01. See also Figure S6.
the lack of human model systems and
the relative inaccessibility of viable human
heart samples.
In this study, we utilized iPSC-derived
cardiomyocytes modified to track
CCNB1 as a model system to study
mechanisms of human cardiomyocyte
replication and polyploidization. Resem-
bling in vivo cardiomyocytes, we observe
that iPSC-derived cardiomyocytes un-
dergo a time-dependent, progressive
replicative arrest and polyploidization.
The ~25% polyploidy that we observe at
differentiation day 40 in this study is
similar to what has been documented in
~8-year-old human hearts (Bergmann
et al., 2015). Using time-lapse imaging of
cardiomyocytes labeled with cTnT-
mCherry and CCNB1-eGFP, we found
that ~75% of CCNB1+ cardiomyocytes endocycle and become
mononuclear polyploid in association with CCNB1 levels that
are likely insufficient to reach the threshold required for nuclear
entry and execution of mitosis, as recently described for other
cell types in mouse embryos (Strauss et al., 2018). This pattern
of polyploidization is distinct from rodent cardiomyocytes, which
are mostly multinuclear polyploid, and further illustrates the
unique replicative characteristics of human cardiomyocytes
and the rationale for the establishment of a human cardiomyo-
cyte model system.
We also uncovered molecular signatures and pathways asso-
ciated with polyploidization using chromatin-state analysis and
scRNA-seq. We found that, while ~96% of regulatory sequences
were similarly activated between diploid and polyploid cardio-
myocytes, polyploid samples exhibited increased activation of




elements overlapping specific transcription factors including
those involved in myofibrillogenesis such as MEF2 family mem-
bers and oxidative stress such as NRF2 and TP53; polyploid
CMs also showed reduced levels of early developmental factors
like brachyury. In addition to providing transcriptional signatures
and pathways associated with replication and polyploidization,
scRNA-seq analyzed by pseudotime uncovered potentially
causal relationships between the function of the sarcomere in
cell-cycle regulation. While previous studies have implicated
the sarcomere’s role in promoting oxidative metabolism (Ulmer
et al., 2018) and cell-cycle arrest (Mills et al., 2017), our study uti-
lized sarcomere-poor cardiomyocytes to directly link the sarco-
mere tometabolic reprogramming and polyploidization in human
cardiomyocytes.
During time-lapse imaging studies, while we confirmed that
sarcomere disassembly is a universal feature of cardiomyocytes
undergoing mitosis, as has been observed in other studies
(Ahuja et al., 2004), we observe that human sarcomere-contain-
ing cardiomyocytes fail to initiate the earliest stages of mitosis,
as CCNB1 is degraded prior to nuclear entry and chromatin
condensation does not occur. Moreover, we find that CCNB1
overexpression is sufficient to both reduce polyploidization and
increase the proportion of G2/M cardiomyocytes, in accord
with replication studies using non-human cardiomyocytes (Bick-
nell et al., 2004; Mohamed et al., 2018), though ploidy was not
specifically addressed. The reduction in polyploidization that
we observed indicates that the presence of sarcomere-contain-
ing myofibrils is not a total block to cytokinesis in our model, in
contrast to what has been proposed in rodent models that
have high rates of multinuclear polyploidy (Engel et al., 2006).
Our study demonstrates that sarcomere-dependent CCNB1 in-
hibition appears to occur through transcriptional repression by
p53 signaling, which, in turn, is activated by a DNA damage
response as a consequence of increased oxidative metabolism.
This is consistent with the previous finding that activation of p53
indirectly attenuates theCCNB1 promoter and induces G2/M ar-
rest in other cell types through a p21-dependent mechanism
(Fischer et al., 2016), as well as other studies that have impli-
cated p53 activity in regulating mouse cardiomyocyte cell
cycling (Nakajima et al., 2004; Pasumarthi et al., 2001) and poly-
ploidy in mouse hepatocytes (Kurinna et al., 2013). While we
could find no changes in histone methylation or acetylation at
the CCNB1 promoter in polyploid cardiomyocytes relative to
diploid cardiomyocytes, our data support a model whereby
p53 activation results in progressive and ultimately irreversible
arrest of human cardiomyocyte mitosis through CCNB1
inhibition.
To understand the functional relevance of sarcomere-depen-
dent polyploidization and replicative arrest, we studied cardio-
myocytes that were rendered non-contractile and sarcomere-
poor by KO of troponin I in an in vivo cell-therapy model of MI.
We found that impaired sarcomere function enhanced cardio-
myocyte engraftment in the heart by 4-fold and enhanced prolif-
eration by >3-fold. While we observed no change in apoptosis
between WT and TnI-DKO conditions, we cannot exclude that
differential survival may occur at earlier time points nor that other
factors additionally contribute to the enhanced engraftment rate
of TnI-DKO CMs. As delivery of in vitro differentiated cardiomyo-
cytes to the injured heart is an alternative to coaxing endogenous
cardiomyocyte regeneration (Chong et al., 2014), our study dem-
onstrates that improved replicative capacity and reduced poly-
ploidization can enhance engraftment, though future studies
will need to assess the functional outcomes of the enhanced
graft size produced by TnI-DKO cardiomyocytes. Additionally,
inhibition of sarcomere assembly did not completely abolish pol-
yploidization nor the age-dependent reduction in CCNB1, indi-
cating that other mechanisms contributing to cardiomyocyte
polyploidization need to be investigated, potentially such that
polyploidization can be minimized while maintaining sarcomere
function through the discovery of additional levers that coax car-
diomyocyte replication. In summary, our study provides a
comprehensive assessment of human cardiomyocyte replica-
tion, refines new sarcomere crosstalk with cell-cycle regulation
through engagement with p53 signaling, and provides a list of
therapeutic targets that could be exploited to coax endogenous
cardiomyocyte replication or enhance cardiac cell therapy for
cardiac regenerative medicine applications.
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Antibodies
Phospho-Cyclin B1 (S133) Cell Signaling Cat. #4133; RRID:AB_2072264
Cyclin B1 ThermoFisher Cat. #MA5-14319; RRID:AB_10987286
cTnT-647 BD Biosciences Cat. #565744; RRID:AB_2739341
cTnT ThermoFisher Cat. #MA5-12960; RRID:AB_11000742
TnI Santa Cruz Cat. #sc-15368; RRID:AB_793465
Alpha-actinin Sigma Cat. #A7811; RRID:AB_476766
Alpha-actinin Abcam Cat. #AB9465; RRID:AB_307264
p53 (ChIP-validated) Cell Signaling Cat. #48818; RRID:AB_2713958
p21 Cell Signaling Cat. #2947; RRID:AB_823586
GAPDH Cell Signaling Cat. #5174; RRID:AB_10622025
Phospho-H2AX (S139) Cell Signaling Cat. #9718; RRID:AB_2118009
Phospho-AMPK (Thr172) Cell Signaling Cat. #2535; RRID:AB_331250
AMPK Cell Signaling Cat. #5832; RRID:AB_10624867
GFP-488 BioLegend Cat. #338008; RRID:AB_2563288
Phospho-Histone H3 (Ser28) 647 BioLegend Cat. #641005; RRID:AB_1279419
Ki67-PE-Cy7 BD Cat. #561283; RRID:AB_10716060
Aurora Kinase A Cell Signaling Cat. #14475; RRID:AB_2665504
b-MHC DSHB Cat. #A4.951; RRID:AB_528385
Peroxidase-conjugated anti-BrdU Roche Cat. #11585860001; RRID:AB_514485
Ki67-647 BD Cat. #558615; RRID:AB_647130
Goat anti-mouse PE Jackson Cat. #115-116-072; RRID:AB_2338627
Goat anti-mouse 488 Invitrogen Cat. #A11001; RRID:AB_2534069
Goat anti-mouse 594 Invitrogen Cat. #A11005; RRID:AB_2534073
Goat anti-rabbit 594 Invitrogen Cat. #A11012; RRID:AB_2534079
Rabbit anti-mouse 488 Invitrogen Cat. #A11059; RRID:AB_2534106
Biotin-SP goat anti-mouse Jackson ImmunoResearch Cat. #115-065-003; RRID:AB_2338557
Goat anti-rabbit IgG HRP Cell Signaling Cat. #7074; RRID:AB_2099233
Goat anti-mouse IgG HRP Invitrogen Cat. #A11008; RRID:AB_143165
H3K27ac (ChIP-validated) Diagenode Cat. #C15410196; RRID:AB_2637079
H3K4me1 (ChIP-validated) Diagenode Cat. #C15410194; RRID:AB_2637078
H3K4me2 (ChIP-validated) Abcam Cat. #AB7766; RRID:AB_2560996
H3K4me3 (ChIP-validated) Diagenode Cat. #C15410003; RRID:AB_2616052
H3K27me3 (ChIP-validated) Diagenode Cat. #C15410195; RRID:AB_2753161
H3K9me3 (ChIP-validated) Diagenode Cat. #C15410193; RRID:AB_2616044
H3K36me3 (ChIP-validated) Diagenode Cat. #C15410192; RRID:AB_2744515
IgG control (ChIP-validated) Cell Signaling Cat. #2729; RRID:AB_1031062
Critical commercial assays
NextSeq 500/550 v2 Illumina Cat. #FC4042005
Absurance H3 Histone Peptide Array Millipore Cat. #16667
SMARTer ThruPLEX DNA-seq Takara Cat. #R400427
NEBNext Library Quant kit New England BioLabs Cat. #E7630
Nextera XT Library Prep kit Illumina Cat. #15032354
HiFi DNA Assembly New England BioLabs Cat. #E2621
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REAGENT or RESOURCE SOURCE IDENTIFIER
Seahorse XF Cell Mito Stress Agilent Cat. #103015-100
Ex-Taq polymerase Takara Cat. #RR001C)
Qubit dsDNA kit Invitrogen Cat. #Q32854
iDeal ChIP Kit for Transcription Factors Diagenode Cat. #C01010055
Fast SYBR Green Master Mix Applied Biosystems Cat. #4385612
HT 8-oxo-dG ELISA kit Trevigen Cat. #4380-096-K
Click-iT Plus EdU Alexa Fluor 647 Flow
Cytometry Assay Kit
Invitrogen Cat. #C10635
AF647 tyramide ThermoFisher Cat. #B40916
Click-iT Plus TUNEL Alexa Fluor 594 Assay
Kit
Invitrogen Cat. #C10618
Experimental models: Cell lines and animals
PGP1 human iPSCs Coriell Cat. #GM23338
PC1 human iPSCs Christine Seidman, Harvard (Hinson et al., 2016)
WTC-11 human iPSCs Gladstone, UCSF A gift from Dr. Bruce Conklin
Sprague-Dawley rats Harlan/Envigo N/A
HEK293T ATCC Cat. #CRL3216
Oligonucleotides
Brunello sgRNA library Addgene Cat. #73178
HR220PA SBI Cat. #HR220PA-1
EditR-Cas9 Dharmacon Cat. #CAS10138
psPAX2 Addgene Cat. #12260
pCMV-VSV-G Addgene Cat. #8454
LentiGuide-Puro Addgene Cat. #52963
pCas9-GFP Addgene Cat. #44719
pLenti CMV GFP Puro Addgene Cat. #17448
PX459v2 Addgene Cat. #62988
Oliognucleotides for custom sgRNA library IDT Custom order











STAR (v.2.5.4a) GitHub https://github.com/alexdobin/STAR






GraphPad Prism GraphPad Software http://survey-smiles.com
FlowJo FLOWJO https://flowjo.com
Fiji NIH https://fiji.sc
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Drop-seq_tools GitHub https://github.com/broadinstitute/
Drop-seq/releases/tag/v1.13
Calcium signal analysis (Pettinato et al., 2020) https://github.com/
TheJacksonLaboratory/
hinson_excel_signal2
Chemicals, peptides, and recombinant proteins
IWP4 Tocris Cat. #5214
CHIR99021 Tocris Cat. #4423
Y-276932 Tocris Cat. #1254
Nutlin-3 Sigma Cat. #444151
Fibronectin (human) Corning Cat. #33016015
Matrigel GFR Corning Cat. #354230
Insulin (human) Sigma Cat. #91077C
Verapamil Tocris Cat. #0654
NAC Alfa Aesar Cat. #A1540914
GeneJuice Transfection Reagent EMD Millipore Cat. #709675
GoTaq Flexi DNA polymerase Promega Cat. #M8297
ROCK inhibitor Y-27632 Tocris Cat. #1254
CHIR99021 Cayman Cat. #13122
Wnt-C59 Selleck Cat. #S7037




Bcl-XL BH4 Millipore Cat. #197217
Cyclosporine A Novartis
IGF-1 Peprotech Cat. #100-11
Pinacidil Sigma Cat. #P154
5-Bromo-20-deoxyuridine (BrdU) Sigma Cat. #B5002
Other
Accutase BD Biosciences Cat. #561527
RPMI 1640 ThermoFisher Cat. #11875093
DMEM (glucose-free) GIBCO Cat. #11966025
Opti-MEM GIBCO Cat. #31985062
Polyethylenimine (PEI) Polysciences Cat. #239662
PEG-6000 Millipore Sigma Cat. #528877
Trypsin-EDTA GIBCO Cat. #25200056
Geneticin (G418) GIBCO Cat. #10131035
Zeocin GIBCO Cat. #R25005
Protein G Dynabeads ThermoFisher Cat. #10004
Puromycin GIBCO Cat. #A1113803
Blasticidin GIBCO Cat. #A1113903
B27 supplement GIBCO Cat. #17504044
B27 supplement (-insulin) GIBCO Cat. #A1895601
Penicillin/Streptomycin GIBCO Cat. #15140122
GlutaMAX GIBCO Cat. #35050061
Sodium lactate Sigma Cat. #71718
N-acetylcysteine (NAC) MilliporeSigma Cat. #1064255
mTeSR1 STEMCELL Technologies Cat. #85850
DAPI Invitrogen Cat. #D1306
TO-PRO-3 Invitrogen Cat. #T3605
(Continued on next page)






Requests for information and resources should be directed to the Lead Contact, Dr. J. Travis Hinson (travis.hinson@jax.org).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Hoechst 33342 ThermoFisher Cat. #62249
MitoTracker Green Invitrogen Cat. #M7514
MitoSOX Red Invitrogen Cat. #M36008
Fetal bovine serum (heat-inactivated) Gemini Cat. #100-106
Protein G Dynabeads ThermoFisher Cat. #10014
PBS GIBCO Cat. #10010049
picoGreen ThermoFisher Cat. #P7589
KOD Hot Start Master Mix MilliporeSigma Cat. #71842-4
SuperSignal West Pico Chemiluminescent
substrate
ThermoFisher Cat. #34580
ProLong Gold Mountant Invitrogen Cat. #P36965
4-20% Mini-PROTEAN TGX gels Bio-Rad Cat. #4561095
RTA PVDF Transfer kit Bio-Rad Cat. #1704272
BSA, Fraction V Fisher Cat. #BP1605
Pyruvate GIBCO Cat. #11360070
Tris-Glycine SDS 10X Fisher Cat. #BP13414
Maxima H Minus Reverse Transcriptase ThermoFisher Cat. #EP0751
Exo I New England BioLabs Cat. #M0293
AMPure beads Beckman Coulter Cat. #A63881
KAPA HiFi Kapa Biosystems Cat. #KM2602
DH5a E.coli cells New England BioLabs Cat. #C2987
Stbl3 E.coli cells Invitrogen Cat. #C737303
Stbl4 E.coli cells Invitrogen Cat. #11635018
4mm cuvettes Bio-Rad Cat. #1652088
RIPA buffer Cell Signaling Cat. #9806
Protease inhibitor cocktail Roche Cat. #11836170001
Phosphatase inhibitor Pierce Cat. #A32957
BCA kit ThermoFisher Cat. #23225
Protein sample buffer ThermoFisher Cat. #39000
Puromycin ThermoFisher Cat. #A1113803
Versene ThermoFisher Cat. #15040066
PBS GIBCO Cat. #14190144
RPMI GIBCO Cat. #11875093
Bovine Serum Albumin Sigma Cat. #A9418
Ascorbic Acid Sigma Cat. #A8960
FBS BioWest Cat. #S1620
0.05% Trypsin-EDTA GIBCO Cat. #25300054
Saponin Sigma Cat. #47036
CryoStor Sigma Cat. #C2874
Diaminobenzadene (DAB) Vector Labs Cat. #PK-6100
Deposited data
scRNA-seq data GEO GEO: GSE147249
CRISPR screen data GEO GEO: GSE147417
ChIP-seq data GEO GEO: GSE130285





Materials generated in this study are available from the Lead Contact upon reasonable request.
Data and code availability
The Gene Expression Omnibus (GEO) accession numbers for the next-gen sequencing data generated in this study are as follows:
GEO: GSE147417 for CRISPR screen data; GEO: GSE130285 for ChIP-seq data; and GEO: GSE147249 for scRNA-seq data.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
iPSC handling and directed differentiation
The parental human iPSC lines used for this study included PC1 for all CCNB1-eGFP studies (Hinson et al., 2016), PGP1 for all cTnT-
KO studies (Coriell Institute Biorepository GM23338) (Cohn et al., 2019; Hinson et al., 2016; Hinson et al., 2015; Pettinato et al., 2020),
andWTC-11 for all TnI-DKO studies (Gladstone UCSFi001-A). All iPSC lines were assessed by karyotype analysis for genomic integ-
rity and maintained in mTeSR1 (STEMCELL Technologies 85850) on Matrigel-coated tissue culture plates (Corning 354230). Media
was replenished daily, and cells were passaged at a 1:6 ratio using Accutase (BD 561527) and 10 mMROCK inhibitor Y-27632 (Tocris
1254) once they reached 80%–90% confluency. PGP1 and PC1 iPSCs were differentiated into CMs through modulation of Wnt/
b-catenin signaling as previously described (Lian et al., 2012). Briefly, Day 0 differentiation was initiated with 12 mMCHIR99021 (Toc-
ris 4423) for 24 hours in RPMI 1640 (GIBCO 11875093) supplemented with B27 minus insulin (GIBCO A1895601) and GlutaMAX
(GIBCO 35050061). On Day 3 of differentiation, cells were treated with 5 mM IWP-4 (Tocris 5214) for 48 hours. On Day 9, cells
were maintained in RPMI with B27 supplement (GIBCO 17504044). On Day 13, metabolic enrichment was performed with
glucose-free DMEM (GIBCO 11966025) supplemented with 4 mM lactate (Sigma 71718) for 24-48 hours, as previously described
(Tohyama et al., 2013). Alternatively, the TNNT2-T2A-NeoR line (CCNB1-eGFP studies only) was enriched via antibiotic selection
with 10 mg/mL Geneticin G418 sulfate (GIBCO 10131035) in RPMI-B27. Following selection, CMs were trypsinized (GIBCO
25200056) and re-plated onto fibronectin-coated tissue culture plates (GIBCO 33016015), unless noted otherwise. CMswere replen-
ished with RPMI-B27 every other day. CM analysis was performed on Day 25-35 unless noted otherwise. For all PGP1 cTnT-KO CM
experiments, PGP1 CMs were used as WT control.
WTC-11 iPSCs were maintained and differentiated similarly as above, with the following modifications. Cells were maintained in
mTeSR1 and passaged with Versene (Thermo 15040066). On differentiation Day 1, media was changed to 1 mM CHIR99021
(Cayman 13122) in mTeSR1. On Day 0, media was changed to 5 mMCHIR99021 in RPMI supplemented with 500 mg/mL BSA (Sigma
A9418) and 213 mg/mL ascorbic acid (Sigma A8960), denoted RBA media. On Day 2, cells were washed with PBS and treated with
2 mMWnt-C59 (Selleck S7037) in RBA media. On Day 4, media was changed to RBA without small molecules. On Day 6, media was
changed to RPMI-B27, which was replenished every other day. CMs underwent metabolic selection on Day 13 with glucose-free
DMEM supplemented with 4 mM lactate for 48 hours. Following lactate treatment, CMs were trypsinized and re-plated onto fibro-
nectin-coated tissue culture plates (Fisher 33-016-015) in RPMI-B27 containing 10 mM Y-27632 + 5% FBS (BioWest S1620).




The homologous recombination (HR) targeting vector (System Biosciences HR220PA-1) wasmodified prior to being used in genome
editing experiments. First, constitutively-expressed RFP was removed in order to prevent conflicting background fluorescence.
Next, T2A-NeoR and mCherry cassettes were obtained as IDT gBlocks and were used to replace the eGFP cassette in the parent
vector via HiFi DNA Assembly (NEB E2621). TNNT2 and CCNB1 ~800bp 50 and 30 HR arm gBlocks were then cloned into the appro-
priate backbones using the built-in multiple cloning sites. Finally, the EF-1a core-driven hygromycin-resistance cassette was re-
placed with a zeocin-resistance cassette to enable separate antibiotic resistance for clonal selection (hygromycin for TNNT2-
T2A-NeoR and TNNT2-mCherry, and zeocin for CCNB1-eGFP). All HR vector propagation steps were performed in DH5a E.coli
(NEB C2987). All CRISPR and primer sequences used for this study are provided in Table S1.
Individual lentiviral single-guide RNAs (sgRNA) were designed using https://zlab.bio/guide-design-resources, obtained from IDT,
cloned into BsmBI-digested lentiGuide-Puro (Addgene 52963), and used in conjunction with lentiviral Cas9 (Dharmacon
CAS10138) for gene knockdown, as previously described (Sanjana et al., 2014; Shalem et al., 2014). All lentiviral vectors were
propagated in Stbl3 E.coli (Invitrogen C737303). The Brunello human genome-wide sgRNA knockout library (76,441 sgRNAs tar-
geting 19,114 human genes and 1,000 non-targeting controls) was obtained as a pooled plasmid library in lentiGuide-Puro (Addg-
ene 73178) and amplified according to the recommended protocol from the Broad Institute’s Genetic Perturbation Platform
(Doench et al., 2016). The custom sub-library containing a 2,032 sgRNA subset from the Brunello library targeting 483 genes
and 100 controls was ordered from IDT, ligated into lentiGuide-Puro with NEB HiFi DNA Assembly, and amplified in Stbl4
E.coli (Invitrogen 11635018).





Isogenic iPSC genetic modifications were engineered using a modified CRISPR/Cas9 protocol adapted from previous studies (Cohn
et al., 2019; Hinson et al., 2015; Pettinato et al., 2020). 8x106 PC1 iPSCs were co-electroporated with 20 mg pCas9-GFP (Addgene
44719), 20 mg of the appropriate hU6-driven sgRNA (designed using https://zlab.bio/guide-design-resources), and 20 mg of the
appropriate HR targeting vector to generate TNNT2-T2A-NeoR, CCNB1-eGFP, or TNNT2-mCherry knock-ins. Cells and plasmids
were mixed in 800 mL PBS, transferred to a 4 mm cuvette (Bio-Rad 1652088), and electroporated (250V, 500uF, N resistance,
4mm; Bio-Rad Gene Pulser II). Electroporated cells were transferred to a Matrigel-coated 100 mm dish containing mTeSR1 and
10 mM Y-27632. The following day, selection was started with the appropriate antibiotic (50 mg/mL Invitrogen Hygromycin B or
50 mg/mL GIBCO Zeocin) to eventually isolate single iPSC clones, which were then manually picked, expanded, and screened via
Sanger sequencing. Generation of the PGP1 cTnT-KO CM model was previously described (Pettinato et al., 2020).
To generate a TnI-DKO CM model, double isogenic knockout of TNNI1 and TNNI3 in WTC-11 iPSCs was performed as follows.
sgRNAs targeting TNNI1 and TNNI3 were designed using the online CRISPR design tool (https://zlab.bio/guide-design-resources)
and ligated into the PX459v2 (Addgene 62988) vector (Cas9-2A-Puro). 3x105 WTC-11 iPSCs were transfected with 1 mg TNNI1-
PX459v2 vector using GeneJuice (Sigma 70967) and selected with 0.5 mg/mL puromycin for 2 days beginning the day after transfec-
tion. After selection, cells were re-plated to obtain and genotype single-cell colonies. After obtaining a homozygous frameshift mu-
tation in TNNI1, the same procedure was repeated for TNNI3.
Flow cytometry analysis
Flow cytometry analysis was performed using a BD Biosciences FACSymphony A5 or BD FACSCanto running FACSDiva software.
On the day of live cell analysis, cells were dissociated and incubated for 30 min at 37C suspended in RPMI-B27 containing 10 mM
Hoechst 33342 (Thermo 62249), 200 nM MitoTracker Green (Invitrogen M7514), and/or 2.5 mM MitoSOX Red (Invitrogen M36008),
where indicated. Cells were thenwashed in PBS, suspended in RPMI-B27 containing 500 nMTO-PRO-3 (Invitrogen T3605), and then
filtered into a 35-mm cell strainer snap cap FACS tube (Corning 352235). Cells were gated on the basis of forward-scatter and side-
scatter, TO-PRO-3 to identify only live cells, and Hoechst-area versus Hoechst-height for doublet discrimination. For analysis of
CCNB1-eGFP cells, Hoechst and eGFP gating was used for cell cycle and ploidy analysis. For mitochondrial analysis, Hoechst
was used to gate for single cells, followed by subsequent analysis of mitochondrial content (MitoTracker) and oxidative stress
(MitoSOX).
For analysis by intracellular staining, suspended cells were fixed with 4% paraformaldehyde for 15 min at room temperature and
then incubated for 1 hour at room temperature with 1:100 primary antibody and 10 mM Hoechst 33342 in PBS + 5% FBS + 0.75%
saponin. After a spin down and wash, cells were immediately analyzed or, if using unconjugated primary antibodies, incubated for
45 minutes at room temperature with 1:200 secondary antibody, either goat anti-mouse 488 (Invitrogen A11001) or goat anti-rabbit
594 (Invitrogen A11012), in PBS + 5% FBS + 0.75% saponin. Final analysis was performed using FlowJo software. The primary an-
tibodies usedwere as follows:mouse anti-cyclin B1 (InvitrogenMA5-14319), rat anti-GFP 488 (BioLegend 338008), rat anti-phospho-
HistoneH3 (Ser28) 647 (BioLegend 641005), mouse anti-Ki67 PE-Cy7 (BD 561283), and rabbit anti-Aurora A (Cell Signaling 14475). 5-
Ethynyl-20-deoxyuridine (EdU) incorporation was detected using the Click-iT EdU 647 flow cytometry kit (Invitrogen C10635) accord-
ing to the manufacturer’s protocol following a 30 min pulse with 10 mM EdU.
Live cell sorting (FACS) and collection for CRISPR screen, ChIP-seq, scRNA-seq, and other experiments was performed using a
BD Biosciences FACSAria Fusion or FACSymphony S6 CT running FACSDiva software. Samples were processed as described
above prior to sorting. Cells were sorted into RPMI-B27 containing 2% FBS.
Drug treatment experiments
For analysis of the cell cycle response to disparate oxygen conditions, CCNB1-eGFP CMs were incubated in normoxia (20%O2, 5%
CO2) or hypoxia (2.5% O2, 5% CO2) conditions for 48 hours, followed by flow cytometry analysis. For analysis of insulin response,
CCNB1-eGFP CMs were cultured in RPMI-B27 without insulin for 48 hours, followed by culturing in RPMI-B27 with or without insulin
for 48 hours before flow cytometry analysis. For Nutlin-3 treatment, CCNB1-eGFP CMs were cultured in RPMI-B27 containing either
DMSO or 10 mM Nutlin-3 in DMSO for 24 hours before flow cytometry analysis. For chronic verapamil treatment, WT CMs were
cultured in RPMI-B27 containing either DMSO or 200 nM verapamil in DMSO starting at Day 9 of cell differentiation and continuing
to protein lysis on Day 20. For acute verapamil treatment, replated CMswere treated with either DMSO or 200 nM verapamil in DMSO
for 1 hour prior to protein lysis. For N-acetyl cysteine (NAC) treatment, CCNB1-eGFP CMs were cultured in RPMI-B27 containing
either DMSO or 500 nM NAC in DMSO starting at Day 9 of cell differentiation and continuing to flow cytometry analysis on Day 20.
Lentivirus production
24 hours prior to transfection, 9x106 HEK293T cells (ATCC CRL-3216) were seeded onto 150 mm plates in 20 mL DMEM (GIBCO
11965092) supplemented with 10% FBS (Gemini 100-106), GlutaMAX (GIBCO 35050061), and 1 mM sodium pyruvate (GIBCO
11360070). The next day, cells were co-transfected with 18 mg of the desired lentiviral transfer vector, 12 mg psPAX2 (Addgene
12260), and 6 mg pCMV-VSV-G (Addgene 8454). The plasmids were pre-mixed with 2 mL Opti-MEM (GIBCO 31985062) and
162 mg polyethylenimine (PEI) and incubated at room temperature for 20 minutes. Meanwhile, 293T were switched into 18 mL fresh
media, followed by gentle dropwise addition of the incubated transfection mixture. Media was replenished the following day and




virus-containing media was harvested at 48, 72, and 96 hours post-transfection, followed by concentration using PEG-6000 as pre-
viously described (Kutner et al., 2009).
Individual gene knockdown and overexpression experiments
Lentiviral-based CRISPR/Cas9 was used to individually knockdown genes directly in CMs. Cas9-expressing CMs were transduced
with lentivirus expressing sgRNA (non-targeting, TP53, or MEIS1) at a MOI of 2 in RPMI-B27. Media was replenished the following
day. CMs were analyzed 5-7 days post transduction via western blot and/or flow cytometry, as described above.
NLS-tagged CCNB1 cDNA was cloned into a lentiviral vector (derived from Addgene 17448) under the constitutive expression of
the EF-1a core promoter. The construct contained a hemagglutinin (HA) tag, and an empty HA-only vector was used as a control.
Lentiviral particles were produced as outlined above. For overexpression, CCNB1-eGFP CMs were transduced with control or
NLS-CCNB1 lentivirus at a MOI of ~2 on Day 9 of differentiation. Flow cytometry analysis was performed on Day 20 to determine
the proportion of CCNB1+ and polyploid CMs.
Time-lapse imaging
To determine CCNB1+ replicative outcomes and expression status, CCNB1-eGFP cTnT-mCherry CMswere subjected to time-lapse
confocal imaging. CMswere plated on fibronectin-coated imaging dishes (MatTek P35G-1.5-14-C) and time-lapse imaging was per-
formed the following day on an Andor Dragonfly 500 microscopy system in confocal mode (40x or 63x oil-immersion objective) using
a Zyla sCMOScamera and anOkolab enclosure to control temperature (37C) and pH (5%CO2). Imageswere taken every 15minutes
for 16-24 hr. Using ImageJ, CCNB1+ CMs were categorized as mononuclear polyploid if CCNB1-eGFP expression was lost either in
the cytoplasm or immediately after nuclear entry. For CMs with sustained nuclear CCNB1-eGFP, mitotic status was determined by
monitoring nuclear morphology for condensation and mitotic commitment by exploiting CCNB1-eGFP’s previously known localiza-
tion to the mitotic apparatus (Clute and Pines, 1999). After nuclear CCNB1-eGFP was lost, cytokinesis or multinuclear polyploidiza-
tion were determined by monitoring cTnT-mCherry morphology to assess successful cellular division or presence of multiple nuclei,
respectively. An example CM undergoing mitosis and cytokinesis is provided in Figure 1E and Video S1. To quantify CCNB1-eGFP
levels from confocal images, mean cellular CCNB1-eGFP signal was measured in ImageJ for all CCNB1+ CMs that exhibited nuclear
CCNB1-eGFP entry, as well as CCNB1+ CMs without nuclear entry within the same field of view.
For comparative time-lapse imaging studies using Nutlin-3 and p53 knockdown, CCNB1-eGFP cTnT-mCherry CMs were sub-
jected to FACS to collect live cTnT+ CCNB1+ CMs (post-G1/S), which were seeded onto fibronectin-coated imaging dishes. After
waiting 2-3 hr for cell attachment, time-lapse imaging was performed on an Andor Dragonfly 500 microscopy system in widefield
mode (20x air objective) using a iXon EMCCD camera and an Okolab enclosure to control temperature (37C) and pH (5% CO2).
Replicative outcomes were determined as described above, and statistical analysis was conducted using one-tailed, ratio-paired
t tests. Nutlin-3 experiments were performed by treating three independent differentiation and sort batches of CMs with DMSO or
10 mM Nutlin-3 just prior to the start of imaging. For p53 knockdown, CRISPR editing (using lentiviral Cas9 + NT versus p53 sgRNA)
was performed 5-7 days prior to sorting of three independent differentiation batches. Both imaging experiments included 200 nMTO-
PRO-3 in order to identify and exclude dead cells. CMs with indeterminate replicative outcomes were also excluded from this
analysis.
CRISPR/Cas9 screen
CCNB1-eGFP TNNT2-T2A-NeoR iPSCs (3x106) were transduced with Cas9 lentivirus at a MOI of < 0.1 and selected with 2 mg/mL
blasticidin (GIBCO A1113903) in mTeSR1. After two passages, the lentiGuide-Puro sgRNA library (Brunello genome-wide or sub-li-
brary) was transduced into 1x108 Cas9-expressing iPSCs at aMOI of < 0.1 and selected with 1 mg/mL puromycin (GIBCO A1113803)
inmTeSR1. The library iPSCswere passaged two times (p2) and cryopreserved in aliquots containing 2x107 iPSCs. These p2 aliquots
were thawed onto 150 mm plates, grown to ~90% confluency, and plated at a seeding density of 8x106 on 100 mm plates (p3). Once
confluent, p3 library iPSCs were differentiated into CMs, subjected to G418 selection, re-plated, and then processed for FACS as
described above. Three populations were collected: CCNB1- diploid (2n), CCNB1- polyploid (4n), and CCNB1+. Three separate dif-
ferentiation batch replicates were processed and collected. Genomic DNA (gDNA) was isolated from sorted cell pellets (QIAGEN
69506) and sgRNAs were amplified for next-generation sequencing (NGS) analysis according to the recommended protocol from
the Broad Institute’s Genetic Perturbation Platform. Each 50 mL PCR reaction consisted of amaximumof 2 mg gDNA, 0.5 mL of Takara
Ex Taq DNA polymerase (Takara RR001C), 5 mL of 10x Ex Taq buffer, 4 mL dNTPs, 0.25 mL of 100 mMP5 stagger-mix forward primer,
5 mL of 5 mMP7 barcode reverse primer, andwater to 50 mL total. The PCR cycling conditions were: 1minute at 95C, followed by 30 s
at 95C, 30 s at 53C, 30 s at 72C, for 29 cycles; and a 10-minute extension at 72C. PCR reactions were electrophoresed, gel ex-
tracted (QIAGEN 28706), and quantified using a Qubit dsDNA high sensitivity assay kit (Invitrogen Q32854) on a Qubit 4 Fluorometer.
Samples were then sequenced on an Illumina NextSeq 550 and analyzed using MAGeCK software (Li et al., 2014). The GEO acces-
sion number for the CRISPR screen data reported in this paper is GSE147417.
Western blotting
To obtain protein lysates, plated cells were washed once in PBS and then lysed in ice-cold RIPA buffer (Cell Signaling 9806)
containing protease inhibitor cocktail (Roche 11836170001), 1 mM PMSF, and phosphatase inhibitor (Pierce A32957). Lysates




were centrifuged to remove cell debris, quantified and normalized via Pierce BCA (Thermo 23225), and then reduced and denatured
in sample buffer (Thermo 39000). Protein lysates were separated on 4%–20%Mini-PROTEAN TGX precast gels (Bio-Rad 4561095),
transferred onto PVDF membranes (Bio-Rad 1704272), washed once in TBS-T (50 mM Tris-Cl, 150 mM NaCl, 0.1% TWEEN-20),
blocked for 1 hour in TBS-T with 5% BSA (Fisher BP1605) or nonfat milk, and then probed overnight with primary antibody in
TBS-T with BSA or milk, depending on the antibody manufacturer’s recommendation. The following day, blots were washed three
times in TBS-T for 15 minutes, probed for 1 hour at room temperature with HRP-linked secondary antibody (Cell Signaling 7076;
7074), and then washed three times in TBS-T for 15 minutes. Signal detection was performed using ECL substrate (Thermo
34580) and a Bio-Rad ChemiDoc MP imaging system. Blot images were digitally processed and analyzed in either Bio-Rad Image
Lab or ImageJ. The primary antibodies used were as follows: 1:1000 mouse anti-p53 (Cell Signaling 48818), 1:1000 rabbit anti-p21
(Cell Signaling 2947), 1:1000 rabbit anti-phospho-CCNB1 (Cell Signaling 4133), 1:1000 rabbit anti-GAPDH (Cell Signaling 5174),
1:500 mouse anti-cardiac troponin T (Invitrogen MA5-12960), 1:1000 rabbit anti-troponin I (Santa Cruz sc-15368; detects both car-
diac (cTnI) and skeletal (ssTnI) isoforms), 1:1000 rabbit anti-phospho-Histone H2A.X (Cell Signaling 9718), 1:1000 rabbit phospho-
AMPKa (Thr172) (Cell Signaling 2535), and 1:1000 rabbit AMPKa (Cell Signaling 5832).
ChIP-seq
Fixed CMpellets were processed for ChIP as previously described (Cotney and Noonan, 2015). Briefly, samples were thawed in 1mL
of 1xCell Lysis buffer and incubated on ice for 20minutes. Cells were lysedwith dounce homogenization and nuclei were collected by
centrifugation (5 min, 2500 g, 4C). Nuclei were resuspended in 300 mL of 1x Nuclear Lysis buffer + 0.3% SDS + 2 mM sodium buty-
rate and incubated on ice for 20minutes. Chromatin was shearedwith aQsonica Q800R1 sonicator systemoperating at amplitude 20
and 2C for 30minutes (10 s duty, 10 s rest). Sampleswere cleared by centrifugation (5min, 20,000 g, 4C) and soluble chromatin was
transferred equally into seven separate tubes with 10% reserved as an input control. SDS concentration was reduced to 0.18%with
ChIP-seq Dilution buffer. Protein G Dynabeads (ThermoFisher) separately preloaded with 2.5-5 mg of antibodies were added to each
chromatin aliquot. Antibodies used in this study were as follows: anti-H3K27ac (C15410196, Diagenode), anti-H3K4me1
(C15410194, Diagenode), anti-H3K4me2 (AB7766, Abcam), anti-H3K4me3 (C15410003, Diagenode), anti-H3K27me3
(C16410195, Diagenode), anti-H3K9me3 (C15410193, Diagenode) and anti-H3K36me3 (C15410192, Diagenode). All Diagenode an-
tibodies came pre-validated for ChIP, and the antibody from Abcam (H3K4me2) was validated using Absurance H3 Histone Peptide
Array (16-667, Millipore). ChIP samples were incubated overnight at 4C on a rotisserie. The chromatin was then immunoprecipitated
on a magnet and the supernatant was discarded. Beads were washed 8 times with 1 mL of 500 mM LiCl ChIP-Seq Wash Buffer and
once with 1mL of TE. Chromatin was eluted from the beads twice with ChIP Elution buffer at 65C for 10minutes with constant agita-
tion. Combined eluates for each ChIP were subjected to crosslink reversal overnight at 65C. Samples were then sequentially treated
with RNase A and proteinase K, purified with a PCR Purification Kit (QIAGEN), and eluted in 40 uL of EB. ChIP samples were then
quantified with picoGreen (ThermoFisher) and ChIP-seq libraries were prepared (R400427, Takara), quantified by qPCR (NEB
E7630L), multiplexed, and sequenced for 75 cycles acrossmultiple flow cells on an Illumina NextSeq 500 instrument using a NextSeq
500/550 High Output v2 kit (75 cycles, Cat No. FC-404-2005).
ChIP-seq data analysis
Quality control was performed on ChIP-seq reads using FastQC (version [v.] 0.11.5) andMultiQC (v.1.1). Trimming for adapters, qual-
ity and length was performed using Trimmomatic (v.0.36) for single end data. ChIP-seq reads were aligned to the human genome
(hg19) using Bowtie2 (v. 2.2.5) (Langmead and Salzberg, 2012). Fragment sizes of each library were estimated using PhantomPeak-
QualTools (v.1.14) (Landt et al., 2012). We then generated P-value-based signal tracks relative to appropriate input controls based on
estimated library fragment size using MACS2 (2.1.1.20160309) (Feng et al., 2012). Bedgraph files for all P-value signals from primary
ChIP-Seq datawere converted to 25 bp resolution and processed formodel training and generation of imputed signals for all samples
using ChromImpute (v1.0.3) as previously described (Ernst and Kellis, 2015). Resulting imputed signal tracks were converted to
bigWig format for display in UCSC genome browser and converted for use with ChromHMM (v1.12) (Ernst and Kellis, 2012) using
ChromImpute’s ExportToChromHMM. Signal files for individual chromosomes for each epigenomewere binarized and segmentation
was performed using the previously published 25-state chromatin models using ChromHMMas previously described (Kundaje et al.,
2015). Following segmentation, annotation of states and generation of genome browser files was performed based on annotations
provided by Roadmap Epigenome. The GEO accession number for the ChIP-seq signals, imputed signal files, and chromatin state
segmentations reported in this paper is GSE130285.
Differential regulatory site activation and motif enrichment
To identify putative regulatory elements that are differentially utilized between mononuclear and multinucleated cardiomyocytes we
compared H3K27ac, H3K4me2, and H3K4me3 signals at promoter and enhancer chromatin state segmentations independently us-
ing DiffBind (v2.10; https://bioconductor.org/packages/DiffBind) in R (v3.4.1). For a specific chromatin signal, uniquely aligned reads
from three replicates of each type of cardiomyocyte were quantified and normalized for input signal at enhancer segments (states 13
through 18 from 25 state model) or promoter segments (states 1 through 4 and 22) using fragment sizes determined by phantom-
peakqualtools (Kharchenko et al., 2008; Landt et al., 2012) and the DBA_SCORE_TMM_MINUS_FULL_CPM function of DiffBind. Dif-
ferential signals were determined by DiffBind using DESeq2 and filtered for a false discovery rate less than 0.1. Differentially enriched




regions were assigned to the single nearest gene up to 1 Mb away and resulting gene lists were assessed for gene ontology (GO)
enrichments using GREAT (McLean et al., 2010). All results from GREAT were retrieved programmatically using rGREAT (v1.14;
https://bioconductor.org/packages/rGREAT. De novo and knownmotif enrichment in differentially activated regions for each histone
modification were determined using HOMER with the options ‘‘-size given -len 8,10,12,14 -mask -gc’’ (v4.9) (Heinz et al., 2010). Re-
sulting HOMER output files were loaded into R using homerkit (https://github.com/slowkow/homerkit) and -log10 transformed P-
values for each motif were compared between regions more active in mononuclear versus multinucleated cardiomyocytes.
Global multi-tissue comparisons of H3K27ac signals
To qualitatively assess similarity of cardiomyocytes generated here to other tissues throughout the human body, we first assembled a
list of all enhancer states (states 13 through 18) from 127 tissues profiled by Roadmap Epigenome, FACS-collected cardiomyocyte
nuclei isolated from fetal and adult heart tissue (Gilsbach et al., 2018), and previously profiled samples from our laboratory (Wilderman
et al., 2018). We next extracted imputed H3K27ac signals from all samples at all enhancer regions using the multiBigwigSummary
command from DeepTools (v3.1.2) (Ramı́rez et al., 2016) excluding all regions blacklisted by ENCODE. The resulting signal matrix
were filtered to remove regions where signal was low (> 10) across all samples (n = 146) and log10 transformed. This transformed
matrix was used to calculate the Euclidean distance between each sample. The resulting distance matrix was then processed
for t-Distributed Stochastic Neighbor Embedding using the Rtsne package (v0.15; https://github.com/jkrijthe/Rtsne) using options
‘‘is_distance = true, perplexity = 10, theta = 0.5, dims = 2, max_iter = 1000.’’ The x and y dimensions were combined with sample
and group labels for plotting with ggplot2 in R.
Single-cell transcriptomics
CCNB1-eGFP and TNNT2-T2A-NeoR CMs for scRNA-Seq were processed as described above in the Flow Cytometry Analysis sec-
tion. For cell sorting, 2n (n = 384 CMs), 4n (n = 384 CMs), and CCNB1+ (n = 384 CMs) were collected into individual 384-well plates
using sorting strategy demonstrated in Figure S1D. We utilized an in-house 384-well plate-based approach for 30 end counting of
transcripts of single cells individually sorted into each well. Each well incorporates a unique reverse transcription (RT) primer (AAG-
CAGTGGTATCAACGCAGAGTAC[12-bp well bar code][8-bp UMI][Tx30]VN) incorporating a well bar code and unique molecular
identifier (UMI) (IDT custom order). scRNA-seq transcript metrics are summarized in Table S4. All RT reagents were dispensed using
an Echo 525 acoustic liquid handler for a final total reaction volume of 1 ul. First and second strand synthesis was performed using
Maxima H Minus reverse transcriptase (Thermo EP0751) and template switching at 42C for 90 min. Reactions from each well were
subsequently pooled into a single tube assisted by a Caliper liquid handler. The pooled libraries were treated with ExoI (NEBM0293L)
at 37C for 45 min to trim single-stranded ends and then cleaned up with AMPure beads (Beckman Coulter A63881). Amplification of
libraries was for 12 cycles using KAPA HiFi-based (Kapa Biosystems KM2602) PCR followed by AMPure bead clean up with quantity
and quality evaluated on Agilent Bioanalyzer. cDNA (1 ng) was fragmented and indexed through Nextera XT Library Prep Kit (tagmen-
tation) (Illumina 15032354), followed by PCRwith indexing primers for sequencing with a final AMPure bead clean up and bioanalyzer
analysis prior to sequencing.
All plates were prepared on the same day with identical reagents, and all libraries were sequenced in a single Illumina NextSeq 500
run using a 75-cycle mid-output kit. Paired-end FASTQs were generated using BCL2Fastq v2.18.0.12 (Illumina) where the first read
contains a 12bp cellular barcode and 8bp UMI and the second read contains 60bp of the mRNA 30 end. Digital expression matrices
were constructed for each pair of FASTQs using Drop-seq_tools v1.13 (http://mccarrolllab.org/dropseq) in the following manner: (A)
bam creation with Picard (v2.9.3) FastqToSam; (B) cell and UMI tagging, filtering, trimming with Drop-seq_tools TagBamWithRead-
SequenceExtended, FilterBAM, TrimStartingSequence, PolyATrimmer; (C) alignment with STAR (v2.5.4a) to GRCh38_74 genome
and Picard (v2.9.3) SortSam; (D) merging and tagging with Picard (v2.9.3) MergeBamAlignment and Drop-seq_tools (v1.13) Ta-
gReadWithGeneExon; (E) expression matrix creation with Drop-seq_tools (v1.13) DigitalExpression. Eight cells were removed due
to high expression of alpha-fetoprotein (AFP), a lineage marker of endodermal differentiation.
Analysis of expression was performed with Seurat (Butler et al., 2018). Briefly, the UMI count matrix was normalized across genes
using a centered log ratio transformation. Cells were then clustered using the FindNeighbors() and FindClusters() commands with a
resolution of 0.8. Non-linear dimensional reduction with UniformManifold Approximation and Projection (UMAP) was then performed
using RunUMAP()with 15 dimensions. Differential gene expression was performed using FindMarkers(). The differentially expressed
genes were filtered for adjusted P-value % 0.05 and then gene set enrichment analysis (GSEA) was performed using the Molecular
Signature Database (Subramanian et al., 2005) to identify enriched Hallmark, Gene Ontology (GO), and Reactome gene sets. Pseu-
dotime analysis was performed with Slingshot (Street et al., 2018) using the Seurat object as input, which identified two independent
pseudotime trajectories. The top 1000 highly variable genes from Seurat were used as the input to predict pseudotime values using
random forest machine learning in order to find genes deemedmost important to predicting pseudotime. The top 100 genes from this
analysis were used for GSEA of each trajectory. The GEO accession number for the scRNA-seq data reported in this paper is
GSE147249.
Immunofluorescence
For immunofluorescence images, cells were fixed on coverslips (Fisherbrand 12-545-100) in PBS containing 4% paraformaldehyde
(EMS 50-980-487), washed three times in PBS, permeabilized and blocked in PBS-T (PBS containing 0.1% Triton-X) with 1% BSA




(Fisher BP1605). Cells were probedwith 1:400mouse anti-alpha actinin primary antibody (SigmaA7811) in PBS-Twith BSA overnight
at 4C, washed in PBS-T, incubated for 1 hour at room temperature in PBS containing 1 mg/mL DAPI (Invitrogen D1306) and 1:400
goat anti-mouse 488 secondary antibody (Invitrogen A-11008), washed, and mounted onto slides (Corning 2948) in ProLong Dia-
mond mountant (Invitrogen P36965). Slides were imaged on an Andor Dragonfly 500 confocal microscope system using a Zyla
sCMOS camera and a Leica DMi8 63x oil immersion lens. Images were acquired using Andor Fusion and analyzed in ImageJ.
ChIP-qPCR
WT and cTnT-KO CMs were fixed and cross-linked using 1% formaldehyde for 15 min at room temperature with gentle tilt-shaking.
The formaldehyde was then quenched by adding glycine to a final concentration of 125 mM and incubating for 5 min at room tem-
perature with gentle tilt-shaking. The cells were thenwashed twice with ice-cold PBS and processed using the iDeal ChIP kit for Tran-
scription Factors (Diagenode C01010055), according to the manufacturer’s protocol. For shearing, sample lysates were sonicated
for 12 cycles using a Branson 250 sonicator at 30% power for 20 s with 60 s cool-down between each cycle. The ChIP-verified an-
tibodies used for immunoprecipitation were IgG control (Cell Signaling 2729) and anti-p53 (Cell Signaling 48818). For qPCR of p53
binding sites on CDKN1A regulatory elements (Nguyen et al., 2018), input (1%) and immunoprecipitated DNA samples were diluted
1:10 and 5 mL were used per 20 mL qPCR reaction using Fast SYBR Green (Applied Biosystems 4385612) and run on a ViiA 7 Real-
Time PCR System. Ct values were used to calculate the percent input (IP relative to input) using the following formula: %Input =
100*2̂ ((Ct input - 6.644) - Ct IP). Primers used for qPCR are listed in Table S1.
Oxidative DNA damage assay
Genomic DNA was extracted (QIAGEN 69506) from WT and cTnT-KO CMs, quantified by Qubit dsDNA high sensitivity assay kit (In-
vitrogen Q32854) on a Qubit 4 Fluorometer, and assayed by ELISA to quantify 8-hydroxy-20-deoxyguanosine (8-OHdG) using the HT
8-oxo-dG ELISA Kit II (Trevigen 4380-096-K), according to the manufacturer’s protocol.
Seahorse OCR assay
WT and cTnT-KO CMs were plated on Seahorse XFe96 Cell Culture Microplates (Agilent 101085-004) at a density of 3x104 CMs per
well and cultured for 5 days before performing the Seahorse XF Cell Mito Stress Test (Agilent 103015-100) according to manufac-
turer’s protocol. Compounds were injected at the following final concentrations and assay times: 1 mM oligomycin at minute 18,
1 mM FCCP at minute 36, and 0.5 mM Antimycin A/Rotenone at minute 54. The test was conducted on an Agilent Seahorse XFe96
Analyzer running the Seahorse Wave Desktop software.
Calcium transients
Analysis of cellular calcium transients was performed using the red genetically-encoded calcium indicator RGECO, as previously
described (Pettinato et al., 2020; Sparrow et al., 2019). WT and cTnT-KO CMs were seeded onto glass-bottom dishes and trans-
duced at a MOI of ~0.3 with RGECO lentivirus two days prior to imaging. For imaging, RGECO-expressing CMs were exposed to
pacing conditions of 1 Hz using a C-Pace EP stimulator (IonOptix) and C-Dish (IonOptix). Fluorescence videos were acquired using
an Andor Dragonfly microscopy system equipped with an enclosed live-cell chamber and iXon EMCCD camera in 561-RFP laser
widefield mode. Ten minutes prior to imaging, cells were treated with DMSO or 200 nM verapamil in DMSO. Whole cell fluorescence
time series data were acquired in ImageJ using the Z axis profile function, followed by automated signal analysis using a custom Py-
thon script (github.com/TheJacksonLaboratory/hinson_excel_signal2).
Cryopreservation and cell preparation for transplantation
Cardiomyocytes used for in vivo studies were cryopreserved on Day 20-22 of differentiation and thawed immediately prior to cell in-
jection, following our previously described protocol (Gerbin et al., 2015; Laflamme et al., 2007). One day prior to cryopreservation,
cells were heat-shocked for 30 minutes at 42C, treated with 10 mM Y-27632 for 1 hour, and dispersed with 0.25% trypsin in EDTA.
Cells were spun down, resuspended in CryoStor (Sigma C2874) at 1x107 cells/mL, and frozen in cryovials. To thaw cryopreserved
cells, cryovials were thawed briefly at 37C, followed by addition of RPMI-B27 + 200 U/mL DNase. Cells were washed and resus-
pended in an RPMI-based pro-survival cocktail containing 50% (vol/vol) growth factor-reduced Matrigel, 100 mM ZVAD (benzylox-
ycarbonyl-Val-Ala-Asp(O-methyl)-fluoro-methyl ketone, Millipore 627610), 50 nM Bcl-XL BH4 (cell-permeant TAT peptide, Millipore
197217), 200 nM cyclosporine A (Novartis), 100 ng/mL IGF-1 (Peprotech 100-11), and 50 mM pinacidil (Sigma P154).
Ischemia/reperfusion injury and cell transplantation
All animal procedures were conducted in accordance with the National Institutes of Health Policy on Humane Care and Use of Lab-
oratory Animals and the University of Washington Institutional Animal Care and Use Committee (IACUC). Fourteen rats were enrolled
per experimental group (injection of WT control versus TnI-DKO CMs). The protocol for ischemia/reperfusion surgery has been pre-
viously published (Gerbin et al., 2015; Laflamme et al., 2007). Briefly, male athymic Sprague-Dawley rats (Harlan/Envigo) were anes-
thetized with intraperitoneal injection of 68.2 mg/kg ketamine and 4.4 mg/kg xylazine, and were intubated and mechanically venti-
lated. To maintain body temperature of 37C, the animals were placed on a heating pad with a rectal probe. A thoracotomy was
performed and the left anterior descending coronary artery (LAD) was ligated for 60 minutes, re-perfused, and the chest was




aseptically closed. Animals underwent a second thoracotomy 4 days after ischemia/reperfusion injury under 5% isoflurane supple-
mented with oxygen. Animals were randomly assigned to one of the two experimental groups. Each animal in the treatment group
received 1x107 CMs resuspended in 100 mL pro-survival cocktail. Cell suspension was injected into three different areas within the
infarct – one into the center of the infarct and two in the lateral infarct border zone. After cell injection, animals received subcutaneous
injections of 5mg/kg Cyclosporine A for seven consecutive days starting the day before cell transplantation. To assess proliferation in
the grafts, all animals received intraperitoneal injection of 50 mg/kg BrdU (Sigma B5002) on days 1, 7, 30, 60, and 90 post-cell
transplantation.
Immunohistochemical analysis
Histological stains and subsequent analysis were conducted as described previously by our group (Gerbin et al., 2015; Laflamme
et al., 2007). Briefly, hearts were perfused with PBS and 150 mM KCl solution after harvesting, fixed overnight in 4% paraformalde-
hyde, sliced into 2 mm thick sections, processed, sectioned, and stained with appropriate primary and secondary antibodies. To
visualize grafts, sections were incubated overnight with mouse b-MHC antibody (Developmental Studies Hybridoma Bank
A4.951, supernatant) followed by a 1-hour incubation with biotin-SP goat anti-mouse antibody (Jackson ImmunoResearch 115-
065-003, 1:500) and developed with diaminobenzadene (DAB, Vector Labs PK-6100) for brightfield images. To quantify cell prolifer-
ation in the grafts, sections were incubated overnight with b-MHC antibody followed by a 1-hour incubation with mouse anti-mouse
488 (Invitrogen A11001). Subsequently, sections were incubated overnight with either Ki67-647 antibody (BD 558615; 1:20) or perox-
idase-conjugated anti-BrdU primary antibody (Roche 1585560, 1:40) followed by AF647 tyramide (Invitrogen B40916) to amplify
BrdU and 10 mM Hoechst 33342. Cardiomyocyte proliferation was quantified by counting b-MHC+ and either BrdU+ or Ki67+ dou-
ble-stained cells from images captured on a Nikon A1R confocal microscope.
Apoptotic cells were identified with Click-iT Plus terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay with
Alexa Fluor 594 dye (Invitrogen C10618) using the manufacturer’s protocol. Briefly, paraffin-embedded tissues sections were depar-
affinized initially in xylene followed by rehydration in serial dilutions of ethanol. Slides were then fixed in 4% paraformaldehyde for
15 minutes at 37C, washed twice in PBS, and permeabilized with Proteinase K at room temperature for 15 minutes. After perme-
abilization, slides were fixed in 4% paraformaldehyde for 5 minutes at 37C. Positive control slides were treated with DNase I and
incubated at room temperature for 30 minutes. Terminal deoxynucleotidyl transferase reaction and Click-iT Plus reaction were per-
formed using the components in the kit. Slides were then incubated with 10 mMHoechst 33342 for 30 minutes in the dark. To identify
grafts, serial sections were deparaffinized and incubated overnight with mouse b-MHC antibody, followed by a one hour incubation
with 1:100 goat anti-mouse 488 secondary and 30 minutes incubation with 10 mM Hoechst 33342 in the dark. Apoptotic cells were
quantified by counting TUNEL+ nuclei in the b-MHC+ positive graft regions from images captured on a high-resolution widefield
microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed and graphed using a combination of R and GraphPad Prism. Data are presented asmean ± standard error of the
mean (SEM). All experiments were conducted with three or more biological replicates (nR 3). Statistical comparisons were conduct-
ed via two-tailed unpaired Student’s t test or ANOVA corrected for multiple comparisons using Holm-Sidak post-test, unless noted
otherwise. Statistical outcomes were defined as p > 0.05 (ns; not significant), p % 0.05 (*), p % 0.01 (**), and p % 0.001 (***).
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